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EphA2, also known as ECK (epithelial cell kinase), is a transmembrane receptor
tyrosine kinase that is commonly over-expressed in cancers such as those of the prostate,
colon, lung, and breast. For breast cancers, EphA2 overexpression is most prominent in
the ER-negative subtype, and is associated with a higher rate of lung metastasis. Studies
conducted to demonstrate the role of EphA2 in a non-cancerous environment have shown
that it is very important in developmental processes, but not in normal adult tissues.
These results make EphA2 a prospective therapeutic target since new therapies are
needed for the more aggressive ER-negative breast cancers. A panel of breast cancer cell
lines was screened for expression of EphA2 by immunoblotting. Several of the
overexpressing cell lines, including BT549, MDA-MB-231, and HCC 1954 were selected
for experiments utilizing siRNA for transient knockdown and shRNA for stable
knockdown. Targeted knockdown of EphA2 was measured using RT-PCR and
immunoblotting techniques.
Here, the functions of EphA2 in the process of metastasis have been elucidated
using in vitro assays that indicate cancer cell metastatic potential and in vivo studies that

reveal the effect of EphA2 on mammary fat pad tumor growth, vessel formation, and the
effect of using EphA2-targeting siRNA on pre-established mammary fat pad tumors. A
decrease in EphA2 expression both in vitro and in vivo correlated with reduced migration
and experimental metastasis of breast cancer cells. Current work is being done to
investigate the mechanism behind EphA2’s participation in some of these processes.
These studies are important because they have contributed to understanding the role that
EphA2 plays in the progression of breast cancers to a metastatic state.
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Chapter 1 –
Introduction & Background
-

Introduction
Cancer has continuously been a significant source of health concern in countries
all over the world (1). It is the second leading cause of death in the United States, lagging
only behind heart disease (1). While there are many types of cancer, breast cancer is one
of particular interest due to the fact that there will be an estimated 209,060 new cases and
40,230 deaths attributed to this disease in 2010 alone (1). In women, it is the most
commonly diagnosed cancer and is the second leading cause of cancer-related deaths (1).
Furthermore, the disparity between the number of new diagnoses and annual deaths
corroborate established findings that breast cancers are considerably variable and may or
may not lead to lethality (2). Disease dissemination to distant sites within the body, a
process called metastasis, is the major contributor to high breast cancer mortality rates
(3). Overcoming the limitations in our understanding of metastasis and breast cancer
biology requires further research and investigation so that new treatments may be
developed and current therapies may be improved (2).

Understanding the Anatomy of the Breast
It is important to begin with a foundation in basic breast anatomy and function in
order to understand the role that these anatomical features and processes play in the
development and progression of breast cancers.
Mammary glands are a unique feature of mammals that function to secrete milk as
a means of providing nourishment and transferring passive immunity to newborn
organisms (4). In humans, the mature female breast consists of approximately 15-20
lobes that radiate outward from the nipple (4) (Figure 1). These lobes are composed of

smaller structures, called lobules (4). Acini are the hollow, sac-like constituents of the
lobules that are responsible for producing and storing milk during pregnancy (4, 5).
Tubular structures, called ducts, form a network of branched passages that initiate at the
lobules and ultimately converge to provide a single route to the exterior through the
nipple (4). The remainder of the breast is composed of adipose tissue and connective
tissue infiltrated with lymph and blood vessels (5).
At the cellular level, both the lobules and the ducts are composed of an inner
luminal epithelial cell layer and outer myoepithelial cell layer (6) (Figure 2). The
myoepithelial cells, also called basal cells, are then followed by a lining of basement
membrane (6, 7). The ductal myoepithelial cells differ from the acinar myoepithelial cells
in that they are layered continuously around the luminal cells, whereas acinar
myoepithelial cells are discontinuously layered (6). While there are many factors that
play a role in characterizing breast cancers, the luminal or basal-like gene expression
patterns seen in various tumor samples has led to the classification of subtypes of breast
cancers and has helped to create a basic level of organization within this otherwise
heterogeneous disease (8).

Figure 1
Basic Breast Anatomy

Reference (9)
Permission to Use Figure Granted by National Cancer Institute

Figure 2
Cellular Components of the Breast Ducts and Lobules

Reference (6)
Permission to Use Figure Granted by Original Publisher, BioMed Central

Predisposition and Risk Factors
Breast cancer may affect any person, but there are certain well-known factors that
indicate a higher likeliness for disease development in select individuals (10). The most
defining risk factors are age and sex (11). While men can be afflicted with this disease,
the number of diagnoses and deaths in men are significantly fewer than in women and the
majority of women diagnosed are normally 50 years of age or older (10, 11). Other
factors that potentiate an increased risk include, but are not limited to, early onset of
menstruation or late onset of menopause, obesity, becoming pregnant at an older age,
familial history of breast cancer, and inheritance of genetic alterations (11). Mutations in
either of the two genes, BRCA1 and BRCA2, are known for heightening the risk of
breast cancer development and are found in 5-10% of patient cases (12). Furthermore,
TP53 and PTEN are examples of two other genes that may harbor mutations and
inheritance of these altered copies increases an individual’s risk of disease development
(13).

Types of Breast Cancer
As aforementioned, breast cancer is a diverse disease originating from a genetic
predisposition or accumulation of spontaneous somatic mutations over time (18).
However, not all breast disorders are considered to be cancerous and many noncancerous conditions do not share the same projected risk of maturing into malignant
disease (14).
Benign breast lesion is a term that collectively describes abnormalities of the
breast that have varying risks for developing cancer, however, this risk may be higher or

lower depending on the specific condition (14). Examples of irregularities that are
considered to have no associated risk of breast cancer development include lipomas,
mastitis, and lymphadenitis (14). On the other hand, atypical ductal and lobular
hyperplasia represent benign lesions that confer a higher potential to become malignant
(14). Despite the disparity between these conditions and their associated cancer
development risk, benign breast lesions are not contributors to breast cancer mortality
rates and, if treated early, will not develop into a malignancy (14).
However, if left untreated, atypical ductal and lobular hyperplasia may lead to
ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), respectively (15).
DCIS and LCIS are considered to be intermediary lesions that are precursors to invasive
cancers (15, 16). DCIS is the more common form of in situ breast cancer and has a higher
tendency to become invasive (15). Invasive forms of the disease have penetrated the
basement membrane and infiltrated the surrounding tissue (15). Approximately 80% of
breast cancer patients have invasive ductal carcinoma (IDC), whereas only 10% have
invasive lobular carcinoma (ILC), also called infiltrating lobular carcinoma (15). Cancer
cells constituting an invasive carcinoma have the potential to spread to regional lymph
nodes and blood vessels where they will be disseminated throughout the body and could
create tumors at distant sites (15).
A less commonly diagnosed type of breast cancer is called inflammatory breast
cancer. Affecting less than 5% of all breast cancer patients, this form of the disease is not
associated with the development of a lump in the breast (17). Rather, its symptoms
include redness, swelling, and inflammation as a result of lymph vessel blockage by

cancer cells and is often misdiagnosed (17). This rare disease is aggressive, highly
metastatic, and has a 5 year survival rate of less than 5% (17).

Heterogeneity within Breast Cancers Creates Subtypes
Transcriptional profile analysis and subsequent hierarchical clustering of data
from a variety of breast tumor samples and breast cancer cells lines have revealed
subtypes with specific genetic expression patterns (8, 13, 18). These subtypes include the
luminal A and B, HER2-overexpressing (Human Epidermal Growth Factor Receptor 2),
normal-like, and basal-like breast cancers (13). Each subtype is associated with a distinct
prognosis and subsequent clinical outcome that makes identification of each patient
tumor subtype both necessary and relevant (19).
Luminal breast cancers makeup approximately 45% of all breast cancers and are
most likely to be low grade and differentiated (20). Identification of luminal tumors is
carried out by staining for keratins 8/18, which are known to be expressed in normal
luminal cells (18). Additionally, these tumor types express the estrogen (ER) and
progesterone (PR) receptors and while luminal tumors are generally positive for these
hormone receptors, variation in their expression leads to the classification of the luminal
A and B groups (8, 13). Several genes, known to encode transcription factors that interact
with ER, are upregulated in luminal-type breast cancers (20). These genes include
FOXA1, GATA3, and PAX2, among others (18, 20). Some of these transcription factors
serve as the driving forces behind luminal breast cancer proliferation and survival (20,
21). Despite intergroup heterogeneity, luminal tumors are clinically more easily treatable
than HER2 or basal-like tumors and are generally associated with a good prognosis (22).

HER2/neu is overexpressed in 25% of all breast cancers as a result of
amplification of the ERBB2 gene (18, 23). HER2-overexpressing tumors express ER to a
lesser degree than luminal tumors (18). In fact, these tumors are more similar to basallike tumors in that they lack expression or upregulation of those genes known to
characterize ER positive tumors (18). HER2 overexpression is associated with tumors
that are less differentiated and have a higher extent of proliferation, invasion, and
metastasis (24). Clinically, HER2 overexpression correlates with a poorer prognosis and
increased mortality rate in comparison to luminal tumors (25).
Finally, the basal-like breast cancers represent about 15% of all breast cancer
cases and are identified by staining for keratins 5/6 or 17 (18, 19, 26). While most of
these tumors share histological features, they are difficult to define universally due to the
lack of common morphological features used during diagnosis (19, 20). As the name
suggests, basal-like carcinomas express gene patterns analogous to those seen in the
normal basal, or myoepithelial cells, of the breast (13, 26). Notably, basal breast cancers
are associated with the “triple-negative” phenotype, meaning they lack ER and PR, and
may exhibit little or no expression of the HER2 growth factor receptor (8). Interestingly,
basal carcinomas have also been associated with the CD44+/CD24-/low expression pattern
and this is virtually unseen in the other subtypes (27). CD44+/CD24-/low cell populations
have been linked to being less differentiated and having higher invasive capabilities, a
property that reflects the poor patient outcome seen in the clinic (19, 27). Basal-like
breast cancers generally develop in patients at a younger age, are aggressive, are likely to
metastasize, have a poor prognosis, and are characterized by a high mortality rate (26).

Breast Cancer Staging
Patients who have breast cancer are diagnosed at various points during disease
progression. Cancer staging has evolved as a way to convey the extent and severity of a
patient’s disease by describing the basic primary tumor characteristics and degree of
spread from the original site, if any (9). Breast cancer staging is useful for clinicians
because it provides them with a common terminology when referring to patient disease
status (9). Furthermore, it provides a useful way to approximate prognosis, employ
treatment strategies, and monitor disease progression (28).
During the mid 20th century, a detailed system of staging, termed the TNM
staging system, was developed (28). This system describes those characteristics of cancer
that are thought to most influence prognosis including tumor size, node involvement, and
identification of metastases (tumor-node-metastasis) (28). The American Joint
Committee on Cancer, AJCC, has since produced a TNM staging of breast cancer that
has undergone constant revisions to reflect the updates in our knowledge of disease
progression (28). The most current TNM staging utilizes clinical, pathological,
recurrence, and autopsy classifications to obtain the most accurate and descriptive stage
of a patient’s disease (9, 28) (Table 1).

Table 1
Basic Breast Cancer Stages
Stage
I

II

Sub-Stage
A
B
A

B
III

A

B
C

IV

Reference (9)

Description
Tumor ≤ 2cm, no spread
- No tumor in breast, but cancer cells in
lymph nodes
- Tumor ≤ 2cm and cancer cell clusters in
lymph nodes
- No tumor in breast, cancer in axillary
lymph nodes
- Tumor ≤ 2cm, axillary lymph node
spread
- 5cm ≥ Tumor ≥ 2cm, no axillary lymph
node spread
- 5cm ≥ Tumor ≥ 2cm, axillary lymph
node spread
- Tumor ≥ 5cm, no axillary lymph node
spread
- No tumor in breast, cancer in axillary
lymph nodes or in lymph nodes near
breastbone
- Tumor ≤ 2cm, cancer in axillary lymph
nodes or in lymph nodes near breastbone
- 5cm ≥ Tumor ≥ 2cm, cancer in axillary
lymph nodes or in lymph nodes near
breastbone
- Tumor ≥ 5cm, cancer in axillary lymph
nodes or in lymph nodes near breastbone
- Tumor any size, spread to chest wall
and/or skin
- Possible spread to axillary lymph nodes
or lymph nodes near the breastbone
No sign of cancer or tumor of any size
that may have spread to chest wall and/or
skin:
Possible spread to lymph
nodes near collar bone
Possible spread to axillary
lymph nodes or lymph nodes
near breastbone
Operable: Cancer found in 10+ axillary
lymph nodes, in lymph nodes below
collarbone, in axillary lymph nodes and in
lymph nodes near the breastbone
Inoperable: Cancer has spread to the
lymph nodes above the collarbone
Cancer has spread to other organs, most
commonly the bones, lungs, liver, or
brain.

Treatment Strategies
The therapeutic significance of the heterogeneous nature of breast cancer is that
each patient case must be assessed individually and a therapy regiment should be
designed based on the results of that assessment (29). Therapeutic decisions rely heavily
on proper staging and analysis of a patient’s disease (30).
Surgery is often the standard mode of treatment for patients with in situ
carcinomas or very early stage invasive carcinomas (30). Radical mastectomies have
been replaced by two types of breast-conserving surgeries (30). First, patients with small,
non-invasive or early stage invasive breast cancers may undergo lumpectomy followed
by radiation therapy (30, 31). Second, in the case of patients who have larger primary
tumors and local advancement of their disease, chemotherapy administration prior to
surgery, also known as neoadjuvant therapy, has proved to benefit some patients by
causing tumor shrinkage and facilitating its removal (30). Furthermore, the newly
developed method of sentinel lymph node mapping, whereby a blue dye is administered
to the surrounding area of a tumor, has reduced the need for axillary lymph node
dissections because the histological state of the sentinel lymph nodes is highly predictive
of the state of the axillary lymph nodes (32). Disease-free sentinel lymph nodes spare the
removal of the axillary lymph nodes which is associated with increased patient morbidity
(32).
In contrast to taking a surgical approach, primary tumors may also be
treated systemically with hormonal agents, various combinations of chemotherapies, or
both (31). The treatment that is administered depends on the hormone receptor status of
the tumor, identifying markers, and the extent of the disease (30-32). Examples of agents

used in the treatment of ER and PR positive breast cancers include tamoxifen,
toremifene, fulvestrant, and progestins (30). For patients with a receptor positive status,
these hormone therapies may be used in combination with other chemotherapies (30).
Targeted therapy also exists for patients with HER2 overexpression including, but not
limited to, trastuzumab and lapatinib (25). Trastuzumab may also be used for patients
with hormone positive disease (30). Those patients whose breast cancer is characterized
as triple-negative are harder to treat because the pathways that drive tumor growth under
these conditions haven’t been fully elucidated (33). Treatment is varied and often
includes the use of platinum-based drugs, taxanes, cetuximab, imatinib, pertuzumab, and
others (33). Chemotherapy is generally the primary therapy administered, but it can also
be used in combination with radiotherapy, and again, the decision to utilize this mode of
treatment is dependent on the characteristics of the patient’s disease (31).
If a patient’s disease is determined to be metastatic at the time of diagnosis,
surgery is usually not the primary choice of therapy because the cancer has already
spread and cannot be contained by removal of the tumor, although it can be beneficial in
rare cases (32). At this point, it is important to identify the number and locations of the
metastases in order to develop an appropriate therapeutic protocol (32). Breast cancer
preferentially metastasizes to the lungs, bone, brain, and liver (32). Metastatic patients
receive several chemotherapeutic and occasionally hormonal agents in addition to
radiotherapy, but often their disease becomes resistant to the available therapies and the
patient ultimately succumbs to their cancer (32, 33). Most metastatic breast cancer cases
are triple-negative (33). As aforementioned, there currently isn’t a recommended
systemic treatment regimen specific for triple-negative cancers (33). Therefore, there is

motivation to find molecular therapeutic targets that are necessary and sufficient for
progression of the cancer to the malignant state in order to broaden the treatment options
available to these patients (33).

Introduction to the Eph Subfamily and EphA2
EphA2 is a member of the largest subfamily of receptor tyrosine kinases (RTKs),
the Eph subfamily (34). EphA1, the first receptor in the Eph subfamily to be discovered,
was identified in 1987 by Hirai et al (35). To date, there are fourteen total members that
are further subdivided into the EphA and EphB subgroups based on sequence homology
(36). The EphA subgroup has nine members, EphA1-8, and the EphB subgroup has five
members, EphB1-6 (36).
Eph receptors bind membrane-bound ligands on adjacent cells, called ephrins, that
are also subdivided into the A and B groups based on the receptor they bind (37). There
are five A-ephrin ligands that are anchored to the cell membrane by a
glycophosphatidylinositol (GPI) linkage (37). In contrast, the B-ephrins are
transmembrane ligands consisting of only three total members (37). In general, EphA
receptors preferentially bind A-ephrins, while EphB receptors preferentially bind Bephrins, although there is some binding promiscuity seen between receptors and ligands
of opposing groups (38). Despite this, all ephrin-Eph receptor binding leads to receptor
autophosphorylation and subsequent activation (34, 39).
Ephrin-Eph receptor interactions have been linked to several functions, mostly in
the developing nervous system where they are involved in axon guidance, cell migration,
synaptic plasticity, and boundary maintenance (38, 39). Furthermore, there are also

implications of Eph-ephrin involvement outside of the nervous system such as during
vascular development (39, 40). While their functions are numerous and diverse, studying
the effect of Eph-ephrin signaling has been difficult due to the functional compensatory
ability of the receptor-ligand complexes (39).
Located on chromosome 1p36.1, EphA2 is a 130 kDa receptor tyrosine kinase
that was discovered in 1990 and was originally named eck, epithelial cell kinase, because
of the abundance of its mRNA and protein expression in epithelial cells (41, 42). The
entire EphA2 gene consists of an open reading frame flanked by either a 5’ or 3’
untranslated region (41). The open reading frame encodes for 976 amino acids and the 5’
and 3’ regions are composed of 113 and 925 nucleotides, respectively (41). Original eck
expression analysis revealed that those tissues with the highest levels of EphA2 include
the skin, ovary, small intestine, and lung (41). Subsequent studies have revealed the
expression and importance of EphA2 function in the breast (43).
Extracellularly, the EphA2 receptor is composed of a NH2-terminal ligandbinding domain, cysteine-rich domain, and two fibronectin-type III repeats (44). The
intracellular domain begins with a juxtamembrane domain (44). This domain has two
tyrosines that can carry out autophosphorylation (44). Next there is a tyrosine kinase
domain, sterile α motife (SAM), and PDZ domain-binding motif (44). The latter two,
located at the COOH-terminal end, interact with proteins that can initiate downstream
signaling such as the src-like adapter protein (SLAP), c-cbl, p85 subunit of
phosphoinositide 3-kinase (PI3K), src-homology domain-containing (SHC) protein, SH2
domain-containing tyrosine phosphatase 2 (SHP2), and focal adhesion kinase (FAK) (34,
44, 45) (Figure 3).

Figure 3
Structure of Eph Receptors and Ephrin Ligands
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EphA2, like its family members, also participates in embryonic development of
the central nervous and vascular system (47). Specifically, it has been identified to be
important in pattern formation, a process that occurs during gastrulation to ensure correct
cell differentiation and growth within the embryo, as well as with proper development of
various tissues within the fetus (48). Additionally, EphA2 is important in correct
placental development during the first trimester of pregnancy (49).
In addition to its expression and involvement in prenatal functions, EphA2 also
plays a crucial role in the young adult and adult organism, where its expression is limited
to proliferating epithelial cells (43, 50). Mammary branching morphogenesis is a
complex process that occurs in the breast shortly after the onset of puberty whereby the
branched ductal network is established (43, 51). EphA2 was found to be the only Eph
family receptor expressed in the terminal end buds, structures known to initiate the
branching process in the breast (43, 51). Post puberty, the expression of EphA2 is
upregulated during the pre-estrous and estrous phases of the estrous cycle (50, 52).
Importantly, EphA2 expression is significantly decreased in differentiated mammary
epithelium (53). This unique expression of EphA2 in the breast and its overexpression in
highly aggressive breast cancers is one of many reasons why this receptor tyrosine kinase
has been a protein of research interest and investigation (53, 54).

EphrinA1 Ligand –EphA2 Receptor Interactions
Ephrin ligands and Eph receptors have a unique relationship in regards to their
interaction and function in normal versus cancerous cells. As previously mentioned,
ephrinA ligands preferentially bind EphA receptors, and the same can be said for B

ligands and receptors (44). This is due to the specific amino acids found in the G-H loop
of ephrins, the location where receptor and ligand binding is thought to occur (44). Slight
differences in the amino acid sequence unique to certain members of the A or B
receptors, such as the EphA4 receptor, are responsible for the promiscuity of binding
between the A and B groups (44).
It is important to remember that both the ephrin ligands and the Eph receptors are
membrane bound (34). Therefore, cell-cell contact is necessary for any ligand to interact
with its receptor (34). An ephrin ligand will bind its receptor through a high-affinity
interface which subsequently causes a lower-affinity interface to be exposed (34, 55).
This lower-affinity interface allows for tetramerization of two ephrin-Eph complexes (34,
55). Transphosphorylation of the cytoplasmic portion of an Eph receptor occurs on the
tyrosine residues in the juxtamembrane region, releasing the inhibition of the kinase
domain and allowing for receptor activation (34, 55).
One of the more interesting features of the EphA2 receptor is its participation in
both tumor suppressive and tumor promoting functions (50, 56). In breast cancer,
EphA2’s tumor promoting abilities are associated with being unbound to ligand, whereas
its tumor suppressive functions result from ligand activation of the receptor (56). This
further translates into differences in the tyrosine phosphorylation state of the EphA2
receptor (56). Ligand stimulation causes receptor phosphorylation that initiates a variety
of downstream activities that negatively regulate migration, invasion, and growth in nontransformed epithelial cells (56). For example, when activated by ligand, EphA2 will
interact with molecules like the SHC protein, GRB2 (Growth Factor Receptor Bound
Protein 2), SLAP, and will initiate PI3K activity (45, 57, 58). This is to be contrasted

with the cancerous state, where EphA2 is not ligand activated and therefore exhibits
significantly reduced tyrosine phosphorylation at sites that would normally be
phosphorylated in response to ligand stimulation (56). Despite this lack of receptor
stimulation by ligand, EphA2 maintains its enzymatic activity (56, 59). The downstream
pathways initiated by EphA2 in its non-ligand bound state are distinct from its ligandactivated state and result in the promotion of migration, invasion, and growth (53, 56,
59). For example, EphA2 has been reported to interact with FAK and E-Cadherin
independent of ligand activation (60). Loss of E-cadherin disrupts ligand-receptor
binding and increases EphA2 association with FAK, ultimately leading to increased ECM
interactions (59, 60).
In summary, the disparity in tyrosine phosphorylation in non-neoplastic and
metastatic cells has important downstream signaling consequences that result in either the
maintenance of a homeostatic state or promotion of cancer progression. These
consequences have not been fully explored, but further study and enhanced understanding
of them would allow for better therapies to be developed for EphA2 overexpressing
breast cancers.

The Role of EphA2 in Cancer
In addition to the many functions of EphA2 in the normal processes of
embryogenesis and in adult epithelial tissues, overexpression of EphA2 has been found in
a variety of aggressive tumor types and is sufficient to drive malignant transformation in
non-transformed cell lines in vitro (53, 61, 62).

Zeng et al. sought to look at EphA2 levels in both cancerous and benign prostate
samples (63). Immunohistochemical analysis revealed high intensity EphA2 staining in
both high-grade intraepithelial neoplasia and adenocarcinomas of the prostate (63).
Conversely, adjacent benign tissue from the same samples showed significantly weaker
staining patterns for EphA2, easily differentiating the neoplastic regions from the normal
regions (63). This study was particularly significant because the expression of EphA2 in
high-grade neoplastic prostatic epithelial cells, a pre-malignant condition, implies that
EphA2 is involved in the early stages of disease progression (63).
EphA2 involvement has also been implicated in pancreatic cancer, the fourth
deadliest cancer in the United States (64). Overexpression of EphA2 in the Capan2
pancreatic cell line, a cell line that is poorly metastatic in vivo with low natural levels of
EphA2, conferred an increase in invasive capability in vitro and increased resistance to
anoikis (64). Furthermore, EphA2 siRNA was used to suppress EphA2 overexpression in
the more aggressive PANC1 and MIAPaCa2 cell lines (64). This resulted in a decrease in
FAK phosphorylation, a molecule whose activation is important in EphA2-mediated
interactions with the extracellular matrix (ECM) during cancer progression (64).
Additionally, EphA2 is commonly overexpressed in ovarian cancer (65). This
overexpression is related to more severe forms of the disease and is associated with poor
patient outcome (65). It has been revealed that a possible reason for this negative
outcome in EphA2 overexpressing ovarian cancer patients is due to the involvement of
the receptor in the process of angiogenesis (66). Angiogenesis is one of the hallmarks of
cancer that is largely responsible for tumor sustenance and growth (66, 67). Targeting
EphA2 in ovarian cancer has been the subject of much investigation (66).

Prostate, ovarian, and pancreatic cancer are only a few examples where EphA2
overexpression is known to play a role in tumor promotion and aggressive behavior (63,
65, 66). Others include esophageal cancer, melanomas, colorectal cancer, cervical cancer,
renal cancer, and non-small cell lung cancer (68-73).

Regulation of EphA2
Due to the association of EphA2 with wide-spread involvement in the most
aggressive cancers, there has been interest in elucidating the mechanisms that regulate it
in a normal environment. Cancer-causing mutations result in the disruption of molecular
regulatory pathways that are necessary for normal cell function and homeostasis (67).
The unveiling of regulatory mechanisms that influence EphA2 expression has provided
insight into how this protein becomes overexpressed in breast cancer and has opened the
door for investigation of the effects of this aberrant upregulation.

Estrogen & c-myc
As previously mentioned, a large majority of the most aggressive breast cancers
do not express the estrogen receptor (8, 74). Furthermore, EphA2 is largely
overexpressed in aggressive and ER negative cell lines (53). Zelinski et al confirmed that
there is an inverse relationship governing ER and EphA2 expression at the protein level
(75). This observation led to the hypothesis that estrogen is responsible for the negative
regulation of EphA2 expression (75). Indeed, multiple non-transformed mammary
epithelial cell lines were used to show a dose-dependent decrease in the protein levels of

EphA2 (75). Furthermore, estradiol treatment of cell lines deficient in ER expression had
no effect on EphA2 expression (75). An interesting finding in this investigation was that
two transformed cell lines had limited expression of both ER and EphA2 (75).
Ultimately, it was discovered that independently high levels of c-myc, a gene target of
estrogen, could also cause inhibition of EphA2 expression (75, 76). Taken together, these
results suggest that as breast cancer progresses towards malignancy, ER expression is lost
and this releases EphA2 from the inhibitory effects of estrogen, allowing it to become
overexpressed on the cell membrane (75, 76).

Ras
Furthermore, Macrae et al have shown that stimulation of the Ras/MAPK
pathway by growth factor receptors initiates transcription and upregulation of EphA2 at
the RNA and protein level (77). Utilization of two MEK inhibitors, U0126 and PD98059,
resulted in a decrease in EphA2 protein levels in a variety of breast cancer cell lines,
further confirming that this receptor tyrosine kinase is downstream of the MAPK
pathway (77).
An important result of this study was the observation that expression of EphA2
receptor and ephrinA1 ligand is mutually exclusive in breast cancer cell lines (77).
EphA2 is overexpressed in the aggressive, mesenchymal-like lines whereas ephrinA1 is
expressed in the less aggressive, more epithelial-like lines (77). One explanation for the
lack of EphA2 in ephrinA1 expressing cells is that ligand activation of EphA2 causes
receptor internalization and subsequent degradation (77).

Interestingly, just as the MAPK pathway stimulates EphA2 expression, it is
simultaneously inhibiting ephrinA1 expression, offering an explanation as to why EphA2
overexpressing cells lack ephrinA1 (77). Though these cells are not expressing ligand,
EphA2 can be activated by ligand presented on ligand expressing cells, leading to
receptor down regulation (77) (Figure 4).
One exception to this relationship is the MDA-MB-231 breast cancer cell line that
has an activating mutation in K-Ras and a B-Raf mutation (77-79). These mutations make
MDA-MB-231 unresponsive to the effects of ligand activation and subsequent MAPK
pathway inhibition (77).

E-Cadherin
Since EphA2 and ephrinA1 are both bound to the plasma membrane and require
cell-cell contact to interact, it was postulated that E-cadherin, a molecule important in
mediating adhesion between epithelial cells, might have a role in regulating EphA2
receptor ligand-dependent activation (59, 80).
A comparison of EphA2 cellular localization in nontransformed mammary
epithelial cells and metastatic cells revealed markedly different distributions of the
receptor (59). In nonneoplastic cells, EphA2 was localized to those areas where cells
were coming into close contact (59). However, EphA2 in metastatic cells was localized to
the membrane ruffles of migratory cells or it displayed a dispersed pattern without
localization to any specific area (59). Subsequent studies revealed that not only do EphA2
and E-cadherin colocalize to the points of cell-cell contact, but disruption of E-cadherin
adhesions resulted in a decrease in the amount of phosphorylated EphA2 and the receptor

Figure 4
Ras Regulation of EphA2 and EphrinA1 Expression
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then became diffusely distributed, as seen in transformed cells (59). Furthermore, EphA2
overexpression in metastatic cells respond to induced expression of E-cadherin by
becoming phosphorylated and localizing to cell-cell adhesion locations (59).
Overall, E-cadherin is thought to influence ligand-dependent activation of EphA2
by stabilizing epithelial cell-cell interactions (59). This stabilization permits binding
between EphA2 and ephrinA1 and functions to maintain normal levels of the receptor in
epithelial tissues (59). It’s important to note that a high cell density is not sufficient to
cause EphA2 phosphorylation and subsequent receptor downregulation, rather, Ecadherin is the necessary component that creates the strong adhesions between cells and
allows for ligand-receptor interaction (59).

P53
p53 is mutated in a large majority of all cancers (81). Considering that p53
normally functions to control cell cycle arrest and cell death, it’s not surprising that
deviation from this regulatory ability would cause havoc on normal cell proliferation and
could ultimately lead or contribute to cancer development (81, 82).
EphA2 contains a binding site for wild type p53 in its promoter indicating that
p53 is a regulator of EphA2 expression at the transcript and protein levels (83). In
response to DNA damage, EphA2 tyrosine phosphorylation and upregulation results from
p53 activation, leading to EphA2-mediated inhibition of cell growth and promotion of
apoptosis (83). It is possible that p53 activating mutations could function to increase
protein levels of EphA2, contributing to the overexpression of the receptor in aggressive
breast cancers (56, 83).

Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP)
It is curious that despite the overexpression of EphA2 in some of the most
aggressive breast cancers, there is limited receptor tyrosine phosphorylation (53, 56, 59).
Investigation into the mechanism behind the lack of receptor phosphorylation in
transformed cells has led to the identification of one particular phosphatase, Low
Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) (84).
Disruption of ligand binding by treating cells with the chemical agent ethylene
glycol tetraacetic acid (EGTA) or by dominant-negative inhibitors resulted in suppressed
phosphotyrosine content (59, 84). Furthermore, addition of phosphatase inhibitors after
treatment of non-neoplastic cells with EGTA hindered the reduction in phosphorylated
EphA2 (84). Subsequent treatment of breast cancer cells with phosphatase inhibitors
alone resulted in an increase in the EphA2 phosphotyrosine content (84).
These studies led to the identification of LMW-PTP, the phosphatase that
regulates EphA2 tyrosine phosphorylation. LMW-PTP is highly overexpressed in a
variety of malignant cell lines, with breast cancer lines being no exception (84). It
functions to dephosphorylate EphA2, thereby stabilizing the protein at the cell surface
(84). The oncogenic activity of LMW-PTP depends on this stabilization of nonphosphorylated EphA2 (84).

Figure 5
Summary of EphA2 Regulation
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Involvement of EphA2 in Metastatic Breast Cancer

Metastasis
The sequential steps that must be carried out by primary tumor cells in order for
them to successfully disengage from the initial tumor site and develop disease at distant
locations are both numerous and complex (85). “Metastasis” is the name given to
describe this process of disease dissemination to secondary, or more, locations from the
primary tumor (85). Metastasis involves transformation of cells at the primary site,
neovascularization, intravasation of transformed cells into circulation, adherence to
vessels in the secondary location, extravasation of the transformed cells into the
surrounding organ, response to stimulatory environmental factors, and finally, growth
within the secondary site (85-87). All of these steps must be completed for metastatic
success (88). Interestingly, studies have shown that entrance into the circulation by cells
from mammary adenocarcinomas was relatively common, but less that 0.01% of
circulating cells survive to develop tumors at metastatic sites (89, 90). This opens debate
about the existence of a select population of cells from the primary tumor that are
predisposed to successfully metastasize (89, 91). However, despite the seemingly
inefficient nature of the metastatic process, metastasis remains the primary contributor to
high cancer patient mortality rates, including those with breast cancer (85, 92, 93).

EphA2 Involvement in Breast Cancer
The RTK EphA2 is a molecule of interest in the study of many cancers, but has
not been fully investigated in the breast cancer setting. Despite this, there is sufficient
evidence to support that such a study would be worthwhile and beneficial.
First, EphA2 has been shown to be overexpressed in both breast cancer cells in
vitro and in clinical specimens (53). More significant is that this aberrant overexpression
of EphA2 is seen only in the triple-negative, basal breast cancer subtype, which are
aggressive and highly metastatic (7, 26, 33). Furthermore, EphA2 overexpression is
sufficient to cause transformation of non-transformed mammary epithelial cells (53). The
significance of these findings is that EphA2 is not simply acting as a marker of tumor
progression, rather, it is a direct player in malignant transformation (56).
Second, there is a deficit in the amount of available therapies for patients with
triple-negative breast cancer (33). Since EphA2 has been shown to have a dominant role
in the progressed state of this disease, investigation into the extent of its participation in
metastasis is certainly an area of interest (33, 53). Furthermore, EphA2 expression in the
developed mammary gland is significantly downregulated in comparison to the extent of
overexpression it exhibits in breast cancers (53, 54). Therefore, it seems likely that
therapy designed to target EphA2 would cause minimal harmful effects to the
surrounding, normal mammary tissue.
Finally, EphA2 is regulated by molecules already associated with advanced stage
cancers. Examples of such molecules include E-cadherin and ER (59, 75). Loss of cellcell contact due to the disruption of E-cadherin mediated adhesions has been implicated
as a mechanism that facilitates the migration and invasion of tumor cells (59). In addition,

hormone receptor status is one of the most important features of a patient’s breast cancer
because of the prognostic ability (75). Upregulation of EphA2 is associated with a
deregulation in both ER expression and E-cadherin expression yet, the extent of tumor
dependence on EphA2 overexpression in metastatic breast cancers hasn’t been
completely elucidated. Exploring the effects of reducing EphA2 in an attempt to
investigate the biology associated with this receptor’s involvement in the metastatic
process would contribute to the greater understanding of the progressive mechanics of
breast cancer.

Specific Aims of the Project
The first specific aim of this project was to stably reduce EphA2 receptor levels in
breast cancer cell lines. The purpose of this aim was to provide proof of the principle that
when EphA2 expression is low in breast cancer cells, they exhibit a decrease in
metastatic potential in vitro and negatively affect tumor growth and development of
metastases in vivo.
The second specific aim of this project was to transiently reduce EphA2 levels in
breast cancer cells using siRNA. The purpose of this aim was to demonstrate that EphA2
can be reduced in breast cancer cells and in established mammary fat pad tumors and this
reduction has a negative affect on properties of metastasis in vitro and tumor growth in
vivo.

Table 2
Summary of Notable Characteristics of the Primary Cell Lines Used in
this Thesis Research

Cell Line

MDA-MB-231

BT549

HCC 1954

Characteristics
-

Reference (94)

KRAS Mutation
BRAF Mutation
ER Negative
Vimentin Positive
EphA2 Expression
ER Negative
Vimentin Positive
EphA2 Expression
HER2/Neu Overexpression
ER Negative
PR Negative
EphA2 Expression
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Materials & Methods

Cell Lines
MDA-MB-231 cells were obtained from Dr. Relda Cailleau’s laboratory at the M.D.
Anderson Cancer Center. These cells were originally isolated from the pleural effusions
of a breast cancer patient of Caucasian descent. A variant of the original cell line was
established from metastatic lesions in a nude mouse that had been injected with MDAMB-231. These variant cells were then transduced with a lentivirus vector expressing
luciferase (Lentigen, Baltimore MD). BT549 and HCC1954 were received from the
American Type Culture Collection. HCC1954 cells were originally isolated from an East
Indian, female patient with TNM stage IIA ductal carcinoma. BT549 cells were originally
isolated from a Caucasian, female patient with ductal carcinoma. See Table 2.

Cell Culture Conditions
MDA-MB-231 Luc cells were maintained in monolayer culture at a temperature of 37°C
and 5% carbon dioxide (CO2). Minimum essential medium (MEM) supplemented with
5% fetal bovine serum (FBS), 1% 100mM sodium pyruvate (GIBCO), 1% non-essential
amino acids (GIBCO), the antibiotics penicillin and streptomycin (GIBCO), L-glutamine,
and vitamins was used to culture these cells. BT549 cells were maintained in monolayer
culture at a temperature of 37°C and 5% CO2. Dulbeccos’s modified eagle medium
(DMEM) supplemented with Ham’s F-12 nutrient mixture, 10% FBS, L-glutamine, and
penicillin/streptomycin was used to culture these cells. HCC1954 cells were maintained
in monolayer culture at a temperature of 37°C and 5% CO2. DMEM-High Glucose

(DMEM-HG) supplemented with 10% FBS, L-glutamine, and penicillin/streptomycin
was used to culture these cells.

Preparation of Whole Cell Lysates
Cells were plated in a 6 well plate to achieve a next-day confluency of 70-80%. After
aspirating the media, cells were washed once with PBS and this was then aspirated as
well. 10 µl of 10 mg/ml stock PMSF in isopropanol and 10 µl of 100 mM stock sodium
orthovanadate (Na3VO4) in addition to a Mini, EDTA-free protease inhibitor cocktail
tablet (Roche Diagnostics) were freshly added to 1 ml of RIPA buffer (50 mM Tris, 150
mM sodium chloride, 0.1% SDS, 0.5% Sodium Deoxycholate, Triton X 100) and then
100 µl this mixture was added to each well. The 6 well plate was put on ice so that each
well could be scraped with a scraper (Corning Incorporated, Costar® 3010), where the
well contents were then transferred into an appropriately labeled microcentrifuge tube.
The collected protein lysates were allowed to incubate on ice for 30 minutes to 1 hour.
After incubating for the specified time, the microcentrifuge tubes containing the protein
lysates were transferred to a centrifuge where they were spun for 20 minutes at 10,000
rpm at a temperature of 4°C. The supernatant was collected and transferred to a separate,
sterile microcentrifuge tube where the protein concentration was then determined using a
Biorad Protein Assay kit and its protocol in addition to the use of a DU®-65
Spectrophotometer.

Immunoblot Analysis
20 µg of protein collected from the whole cell lysates was combined with Laemmli
Buffer (Sigma) and boiled for 5 minutes. Protein samples were then separated by sodium
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) set at 100 volts. After
separation, protein was transferred to a nitrocellulose membrane (Biorad) also set at 100
volts. Membranes were blocked using 5% milk in TBST. The following describes the
primary antibodies used to probe the nitrocellulose membrane and the specific conditions
required for each: Anti-Eck/EphA2 (Millipore, Cat#05-480) diluted 1:1000 in 5%FBSTBST, anti-EGFR (Upstate, Cat#06-847) diluted 1:2000 in TBST only, anti-actin (Sigma,
Cat#A2066) diluted 1:5000 in 1%FBS-TBST. The following describes the secondary
antibodies used: Anti-rabbit IgG (Cat#NA934V) and anti-mouse IgG (Cat#NA931V)
secondary antibodies (Amersham Life Science ECL Western Blitting Analysis System).
GE Healthcare ECL Western Blotting Detection Reagents (Cat#RPN2106) were used for
detection.

Isolation of RNA and Quantitative Real Time Polymerase Chain Reaction
Cells were plated in a 6 well plate and grown to 70-80% confluency. RNA was isolated
using the Array Grade Total RNA Isolation Kit (SA Biosciences, Cat#GA-013) according
to its protocol. Isolated RNA was then treated with TURBO DNA-free reagents (Ambion,
Cat#AM1907) and made into cDNA by the process of reverse transcription using the
High Capacity DNA Archive reagents (Applied Biosystems). Each test well on the PCR
plate had a total reaction volume of 25 µl which was a mixture of 1.25 µl of 20X Gene
Expression Assay Mix (Applied Biosystems), 12.5 µl of 2X TaqMan Universal PCR

Master Mix (Applied Biosystems), and 11.25 µl of 200 ng cDNA that was diluted in
RNase-free water. Duplicates of each sample were tested with 18S in each sample tested
as the intrinsic positive control. After plate preparation, the 7500 Real-Time PCR System
(Applied Biosystems) was used to carry out the reaction and data was converted into
cycle threshold (∆CT) measurements. qRT-PCR was performed for EphA2 and EGFR in
this way.

siRNA Transfection
Cells were grown in a 6 well plate to 70-80% confluency. The next day, transfection
mixtures were prepared. Control cells were treated with 400 µl of serum-free medium
only. Control cells for the transfection reagent were treated with 400 µl of serum-free
medium with 12 µl of HiPerFect Transfection Reagent (Qiagen, Cat#301705). Cells
treated with the non-targeting siRNA were treated with 400 µl of serum-free medium, 12
µl of HiPerFect Transfection Reagent, and 1.5 µl of the negative control siRNA (Ambion,
Cat#AM4613). Cells treated with EphA2-targeting siRNA #1 were treated with 400 µl of
serum-free medium, 12 µl of HiPerFect Transfection Reagent, and 1.5 µl of the EphA2targeting siRNA ID: 146479 (Ambion, Cat#AM16708A). Cells treated with EphA2targeting siRNA #2 were treated with 400 µl of serum-free medium, 12 µl of HiPerFect
Transfection Reagent, and 1.5 µl of the EphA2-targeting siRNA ID: 242385 (Ambion,
Cat#AM16708). After preparation of transfection mixtures, culture medium was
aspirated, mixtures were added to the appropriate wells, and cells were incubated for 5-6
hours. After incubation, 1.9 ml of the appropriate serum-containing medium was added to

each well and cells were incubated for 72 hrs at which point they would be used for
various assays.

Migration Assay
Approximately 1x105 cells were plated into the upper, non-coated chamber of one of 24
well inserts with an 8 micron pore size (BD Biosciences, Cat#354578). Cells were plated
in serum-free medium in the upper chamber and were placed in the lower chamber which
contained either serum-free medium + 0.1%BSA or serum-free medium containing
0.1%BSA and EGF (Invitrogen, Cat#13247-05) as a chemoattractant. Migration plates
were placed in the incubator and cells were allowed to incubate for 6 hours. Cells that did
not migrate were wiped away with a cotton swab. Cells that had migrated to the lower
surface of the membrane were fixed and stained with the Fisher HealthCare PROTOCOL
Hema 3 Manual Staining System (Fisher Scientific Company L.L.C.). Membranes were
allowed to dry before being cut away from the chamber and placed on microscope slides
(Fisher Scientific, Cat#15-188-51) with PerMount (Fisher Scientific) and covered with a
cover slide (Corning 24x40mm, Cat#2935-244). Migrated cells were then counted.

ELISA for VEGF
2.5x105 cells were plated in a 6-well plate. The next day, the medium was aspirated and
1ml of medium was added back in overnight and supernatant was collected the next day.
VEGF capture antibody (R&D Systems, Cat#AF-293-NA) was added to a 96 well E1A
plate (Costar 9018) the day before ELISA was performed. Wells were then washed with
wash buffer (PBS+0.05%Tween 20) and blocking solution was added (PBS with 1%

BSA, 5% sucrose, 0.05% sodium azide) for 1 hour. Wells were washed with wash buffer.
VEGF standards (R&D Systems, Cat#293-VE) and sample supernatants were added to
appropriate wells for 2 hours. Wells were washed with wash buffer. VEGF detection
antibody (R&D Systems, Cat#BAF293) was added to the wells for 2 hours. Wells were
washed with wash buffer. Streptavidin HRP (R&D Systems, Cat#DY998) was added to
wells for 20 min. Wells were washed with wash buffer. Substrate solution [1:1 mixture of
color reagent A (H2O2) and color reagent B (tetramethylbenzidine), R&D Systems,
Cat#DY999] was added to wells for 25 min. Stop solution (1M H2SO4) was added to the
wells. Plate was read within 30 min. using the DU®-65 Spectrophotometer and VEGF
concentrations were calculated based on standard curve values.

Co-Immunoprecipitation Assay
5x106 cells were plated in a 10 cm dish with 10 ml medium. When cells were 80%
confluent, they were serum starved overnight and stimulated with 50ng/ml EGF for 15
minutes the next day. The medium was aspirated, cells were washed once with cold PBS,
and 1ml of cold PBS was added to the dish to collect the cells. Cells were centrifuged at
4°C at 3000rpm for 5-10 minutes. The supernatant was dumped and cell pellets were
lysed with 500 ml TNE buffer with inhibitors. Cell and buffer mixture was allowed to
rotate for 1 hr at 4°C and then spun down at 12,000 rpm for 15 minutes at 4°C. The
supernatant was transferred into a clean tube and the protein concentration was measures.
Samples consisting of 20 µg of protein were prepared and set aside to be used for whole
protein lysates control. 100 µg protein was taken from each protein sample and mixed
with TNE buffer to take the total volume up to 1 ml. 5 µg of anti Eck/EphA2 antibody

(Millipore, Cat#05-480) was added to each sample and allowed to rotate at 4°C
overnight. The next day, 25 µl of beads was taken per sample and washed with 1 ml TNE
buffer three times. After washing, TNE buffer was added to the bead volume in a 1:1
ratio. 25 µl of the bead/TNE buffer mixture was added to each 100 µg protein sample and
was allowed to rotate for 1-2 hrs at 4°C. Samples were spun down and beads were
washed with 1 ml TNE buffer three times. 2x Laemmli buffer was added in a 1:1 ratio to
the protein samples and also to the aliquots of 20 µg whole protein samples. All samples
were boiled for 5 minutes. Proteins were then subjected to SDS-PAGE and western blot
analysis to look at EGFR protein expression.

Lentiviral Delivery of shRNA for Stable Silencing of EphA2
Knockdown cell lines were made by using the Invitrogen website BLOCK-iT RNAi
Designer to find shRNA sequences that had been ranked to indicate knockdown
probability. Three highly rated EphA2 target shRNA sequences were selected: LV3:
GGCTGAGCGTATCTTCATTGA; LV4: GCGTCATCTCCAAATACAAGC; LV5:
GGTGATGAAAGCCATCAATGA. Sequence information was provided to the Viral
Core Laboratory of the Department of Cancer Biology to prepare lentivirus with shRNA
to EphA2. Sense and antisense EphA2-targeting oligonucleotides and a non-targeting
control shRNA oligonucleotide (TTCTCCGAACGTGTCACGT) were created to have a
hairpin structure and sticky ends. The EphA2 targeting and non-targeting shRNA
oligonucleotides were then cloned into the pLVTHM expression vector (Addegene,
Cat#12247). EphA2 shRNA knockdown lentivirus and non-targeting shRNA lentivirus
were generated by transfecting the packaging plasmid (2nd generation including PAX2

and MD2G; Addgene, Cat#12259 and 12260) with the EphA2 expression plasmid into
293T cells. MDA-MB-231 Luc and BT559 cells were plated and grown to 70%
confluency. Control cells were treated with 250 µl of non-targeting control virus, 750 µl
of regular medium, and 3µg/ml of polybrene. Test cells were treated with 500 µl of either
LV3, LV4, or LV5 in addition to 500 µl of regular medium and 3 µg/ml of polybrene.
Cells were incubated with the virus mixtures for 24 hours, after which the mixtures were
aspirated and fresh medium was added. Cells were incubated and allowed time to grow.
Cells were sorted at the M.D. Anderson Cell Sorting Facility based on expression of
GFP.

Agarose Colony Formation Assay
Standard 2x MEM was prepared from 10x MEM liquid. 20 ml of the 10xMEM, 75 ml of
double distilled H2O, 2.9 ml of sodium bicarbonate (7.5% solution), and 2.1ml of penstrep solution were mixed together. After mixing, the solution was filtered for
sterilization and stored. To begin the assay, 1% and 0.6% agarose solution needed to be
made from standard 2% agarose. The 2% agarose solution was warmed in the microwave
and then mixed 1:1 with 2x MEM to make 1% agarose solution. In order to make 0.6%
agarose solution, the 1% agarose solution was further diluted using serum-free MEM.
1ml of 0.6% agarose solution was added to each well of a 6 well plate, or according to
how many samples there were including a duplicate. The 0.6% agarose solution was
spread quickly and left in the hood to solidify. Cells were harvested and counted. The cell
layer was mixed in proportions of 1% agarose, serum-free MEM, FBS (either to make
10% or 1% FBS), and cell suspensions in order to achieve a concentration of 0.3%

agarose, 10% or 1% FBS, and 1x103 cells in a final volume of 1.5 ml. 1.5 ml of each cell
solution is now added to the appropriate well on top of the 0.6% base agarose layer. The
plates were allowed to sit at room temperature for 30 min-1 hr before being put in the
incubator for approximately 14-21 days. Every couple of days, a small amount of
medium (0.5 ml) was added to the agarose cultures to prevent the gel from drying.

Immunocytochemistry for Fluorescent and Confocal Imaging
Cells were plated on chamber slides at 7x104 cells per chamber and incubated overnight.
The next day cells were fixed with acetone, washed with PBS, and blocked with protein
block (4% Fish gelatin in PBS, supplied by the Core Facility). EphA2 antibody
(Millipore, Cat#05-480) was applied to cells and incubated in the cold room overnight.
Cells were washed, protein blocked, and secondary antibody was applied for 1 hour.
Alexa 488 goat-anti-mouse (MolPrb, Cat#A11029) secondary antibody was used to stain
cells for fluorescent imaging and cy3 goat-anti-mouse secondary antibody was used to
stain cells for confocal imaging (Jackson ImmunoResearch, Cat#111-166-047). Cells
were washed, protein blocked, and the EGFR primary antibody (Santa Cruz, Cat#sc-03)
was applied overnight in the cold room. Cells were washed, protein blocked, and EGFR
secondary antibody was added for 1 hour at room temperature. Alexa 594 anti-rabbit
secondary (Invitrogen, Cat#A11037) was used to stain cells for fluorescent imaging and
cy5 donkey-anti-rabbit secondary (Jackson ImmunoResearch, Cat#711-176-152) was
used to stain cells for confocal imaging. Cells were washed and counterstained with
Hoescht (for fluorescent imaging of nuclei; Invitrogen, Cat#H3570) or cytox green (for

confocal imaging of nuclei). Cells were washed, slides were mounted with propylgallate,
covered, and stored in the cold room protected from light.

Animals
Female athymic nude (NCr-nu/nu) mice were purchased from the Charles River
Laboratory (Wilmington, MA) when they were four to five weeks old. The animals were
housed in a facility that is approved by the American Association for Accreditation of
Laboratory Animal Care.

Mammary Fat Pad Tumor Growth
Each experimental group consisted of 5-10 mice. Mice were anesthetized using Metofane
(Pitman Moore, Inc.; Washington, NJ). Once anesthetized, an incision approximately 5
mm in length was made in the skin covering the lateral thorax to expose the mammary fat
pad. A 27 gauge needle was used to inject 5x106 cells in 0.1 ml PBS into the mammary
fat pad of each animal.

Experimental Metastasis
1x106 breast cancer cells suspended in a volume of 0.2 ml PBS were injected
intravenously (i.v.) in the lateral tail vein of each mouse. A total of 5-10 mice were used
per experimental group. Animals were watched closely until they were approaching death
or until 10 weeks post injection. At either of these time points, the animals were
sacrificed and the lungs were collected to be examined for metastases. Additionally, since
the MDA-MB-231 Luc cells contain a luciferase gene, animals were monitored for lung

metastases approximately three weeks post-i.v. injection of the cells. Mice were injected
i.p. with 0.2 ml of 15 mg/ml luciferin and imaged for bioluminescence using a Xenogen
IVIS Imaging System. The extent of bioluminescence could be measured using the ROI
(Region of Interest) tool provided in the imaging software.

Liposomal and Chitosan Nanoparticle Treatment
Cells that had been injected into the mammary fat pad were allowed to grow until tumors
were established and had reached an approximate volume of 75 mm3. Concurrently, the
DOPC liposomes and nanoparticles containing control or EphA2-targeting sequences
were prepared and provided by the laboratories of Dr. Anil Sood and Dr. Gabriel LopezBerestein using siRNA sequences purchased from Sigma Genosys. siRNA known and
shown to target EphA2 mRNA (5’-UGACAUGCCGAUCUACAUG-3’) and siRNA
known and shown to have no human mRNA target (5’-UUCUCCGAACGUGUCACGU3’) were used for liposomal and nanoparticle incorporation. Briefly, incorporation of
DOPC and siRNA involved mixing the two in the presence of tertiary butanol, then
Tween 20 was added, and finally an acetone/dry ice bath was used to freeze the mixture
before being lyophilized (95). Preparation of the siRNA and nanoparticles involved the
addition of TPP (thiamine pyrophosphate) and siRNA to a chitosan nanoparticle solution
where the siRNA chitosan nanoparticles spontaneously formed (96). PBS, DOPC
liposomes, or chitosan nanoparticles were injected i.v. twice weekly (150 µg/kg) for four
weeks. Those groups that also received chemotherapy were injected i.p. with paclitaxel
(24 mg/kg) once weekly in a PBS-glucose solution for four weeks. At the end of the

study, tumors were weighed and tumor tissue was collected for frozen sections, paraffin
sections, and it was snap frozen for protein isolation.

Homogenization of Tumor Tissue for Protein Analysis
During mammary fat pad tumor collection, some tissue was snap frozen in liquid nitrogen
for later protein analysis. Samples were homogenized while still frozen in TNE lysis
buffer that consists of 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 2 mM EDTA, 1 mM
Na3VO4, 1 mM PMSF, and an inhibitor cocktail tablet. After homogenization, NP-40
(Sigma, Cat#N-6507) was added to each sample (1%v/v) and mixed well. Samples were
incubated on ice for 30 min-1 hr. Homogenized tissues were then centrifuged at 10,000xg
for 10 minutes at 4°C. The supernatant was removed and transferred to a clean
microcentrifuge tube where it was centrifuged again. This process continued until a clear
lysate was obtained. Protein concentrations could then be measured and were subjected to
western blot analysis.

Immunohistochemistry for CD31 on Frozen Sections
Slides were fixed in acetone, washed, and incubated in 3% H2O2 in methanol. Sections
were then protein blocked and the primary antibody (BD Pharmingen, Cat#553370) was
added 1:1000 in protein block overnight at 4°C. The next day, slides were washed and the
HRP secondary antibody (Jackson ImmunoResearch, Cat#112-035-167) was added 1:200
in blocking solution for 1hr at room temperature. Slides were washed, diaminobenzidine
(DAB; Research Genetics, Cat# ) was added, and then rinsed. Sections were

counterstained with Gill’s Hematoxylin and rinsed. Finally, sections were allowed to dry
and were mounted with Universal Mount.

Immunohistochemistry on Paraffin Embedded Tissue
For Ki-67 staining, slides were dewaxed. Antigen retrieval in citrate buffer (0.1M) was
carried out. Slides were washed, incubated in endogenous peroxide blocking solution
(3% hydroxyperoxide), and washed again. Protein blocking solution (TBST + 5%NGS)
was applied to the slides for 1hr at room temperature. Primary antibody (Epitomics,
Cat#4203-1) was added 1:200 in blocking solution and incubated at 4°C overnight. Slides
were washed and secondary antibody (Jackson ImmunoResearch, Cat#111-036-047) was
applied to sections 1:250 in blocking buffer and incubated for 1hr at room temperature.
Slides were washed and incubated in DAB. Slides were washed, stained with
hematoxylin, washed again, and then left to air dry before being mounted in Permount.
For cleaved caspase 3 staining, slides were processed (de-waxed, antigen retrieval, and
blocked for endogenous peroxidase) as described above. Antibody to cleaved caspase 3
(Cell Signaling, Cat#9661) was diluted 1:200 in protein blocking solution and incubated
overnight at 4°C. The secondary antibody, DAB, and hemotoxylin counterstain was as
described above.

Densitometry
The Image J program was downloaded and used to quantify protein levels revealed by
western blot analysis. Each protein band was compared to its corresponding actin band by
calculating the ratio. This ratio could then be compared with the other sample ratios.

Statistical Analysis
The results of the in vitro and in vivo studies were analyzed for their significance using
the Student’s T-test. A p-value of less than or equal to 0.05 was considered statistically
significant. Calculations were carried out using Microsoft Office’s Excel application.
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Introduction
Stably reducing the levels of EphA2 in breast cancer cells was necessary in order
to demonstrate that cells with low EphA2 expression would have decreased metastatic
potential. Introducing synthetic siRNA into cells and allowing the natural cellular RNA
interference process to use these siRNAs to silence protein expression is a powerful way
to study the effects of EphA2 knockdown in metastatic breast cancer cell lines and in
mouse xenograft models (97). However, a drawback of this method of RNAi pathway
activation is that the effect of receptor expression silencing is transient, lasting only a few
days (97). An alternative method of RNAi pathway activation can be mediated through
the use of shRNAs (97). Plasmid vectors containing shRNA for the gene of interest can
be inserted into a packaging cell lines which also contains plasmids encoding lentiviral
proteins (97, 98). The gene of interest is then packaged into the virus which can be used
to transduce a particular cell line where it will be randomly inserted into the host cell
genome and will ultimately be incorporated into the RNAi pathway (97, 98).
Direct cellular delivery of siRNA, subsequent processing by the enzyme Dicer,
and incorporation into RISC occurs in the cytoplasm of the cell (97, 98). While shRNA
processing also occurs in the cytoplasm by Dicer, it is first processed in the nucleus by an
enzyme called Drosha before cytosolic exportation (97, 98). This second method of
RNAi pathway activation offers the advantage of longer-term silencing (98). The
significance of this long-term silencing is that it allows investigation into the effects of

EphA2 receptor depletion over a period of time when the cellular mechanics are stably
altered (98). The mechanism of using lentiviruses containing EphA2 targeting sequences
for stable receptor depletion was adopted in order to conduct in vitro and in vivo studies.
Three EphA2-targeting sequences were separately inserted into lentivirus vectors
in an attempt to achieve a stable knockdown of EphA2 receptor levels. These three
viruses are termed LV3, LV4, and LV5. Additionally, there is control lentivirus that
contains a scrambled, non-targeting sequence and it is termed LVNC. These virus names
were used throughout the experiments to designate the cells that were transduced with a
specific lentivirus. For example, MDA-MB-231 Luc cells transduced with LV3 were then
termed MDA-MB-231 Luc LV3.

Results: In vitro Studies

Demonstration of Stable EphA2 Knockdown in MDA-MB-231 Luc, HCC1954, and
BT549 Breast Cancer Cell Lines after Transduction with Lentivirus Containing
EphA2-Targeting Constructs
Lentiviruses were designed that contained EphA2-targeting constructs for the purpose of
stable protein knockdown. One (LV3) of the three (LV3, LV4, LV5) viruses created,
each containing a unique targeting sequence, turned out to effectively reduce EphA2
receptor levels stably compared to the control (LVNC) that contains a non-targeting
sequence. After transduction, cells were sorted based on GFP expression which indicates
successful uptake and integration of viral information into the target cells. BT549 and
MDA-MB-231 Luc cells transduced with LV3 showed the most significant protein
reduction as revealed by western blot analysis and subsequent densitometry analysis.
Further qPCR analysis confirmed the knockdown of EphA2 in the LV3 cell lines (data
not shown) (Figure 6).

Figure 6. Demonstration of EphA2 Knockdown in MDA-MB-231 Luc, HCC1954,
and BT549 Cell Lines after Transduction with Lentivirus
(A) Western blot analysis of protein lysates collected from HCC1954 cells that had been
left untreated, treated with lentivirus containing a non-targeting construct, or treated with
one of two lentiviruses containing EphA2-targeting constructs revealed that LV3 was
most successful at reducing EphA2 protein levels (left). Actin was used as a control to
ensure equal protein loading. Densitometry analysis confirmed the results of the western
blot (right). LV3 was not as successful at stably reducing EphA2 protein levels in this cell
line in comparison to the other two cell lines. (B) Western blot analysis of protein lysates
collected from MDA-MB-231 Luc cells that had been left untreated, treated with
lentivirus containing a non-targeting construct, or treated with one of three lentiviruses
containing EphA2-targeting constructs revealed that LV3 was most successful at
reducing EphA2 protein levels (left). Actin was used as a control to ensure equal protein
loading. Densitometry analysis confirmed the results of the western blot (right). (C)
Western blot analysis of protein lysates collected from BT549 cells that had been left
untreated, treated with lentivirus containing a non-targeting construct, or treated with one
of three lentiviruses containing EphA2-targeting constructs revealed that LV3 was most
successful at reducing EphA2 protein levels (left). Actin was used as a control to ensure
equal protein loading. Densitometry analysis confirmed the results of the western blot
(right).
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MDA-MB-231 Luc and BT549 Cells Transduced with LV3 Show Reduced
Migration Towards the Chemoattractant EGF Compared to the Control
MDA-MB-231 Luc cells treated with lentivirus containing either the non-targeting
control or EphA2-targeting construct were plated in a transwell chamber and stimulated
by either 0.1%BSA or 50ng/ml EGF. MDA-MB-231 Luc LV3 cell migration was
attenuated when stimulated by EGF in comparison to the 231 Luc LVNC cells where the
number of migrated cells towards EGF was greater than towards 0.1%BSA. This result
was significant when the number of MDA-MB-231 Luc LV3 cells that had migrated
towards EGF was compared to the MDA-MB-231 Luc LVNC cells that had migrated
towards EGF (Figure 7a). This migration experiment was repeated in the BT549 cell lines
that had been transduced either by the EphA2-targeting lentivirus or the non-targeting
lentivirus. The result was similar to that seen with the MDA-MB-231 Luc cells where the
BT459 LV3 cells showed attenuated migration when compared to the BT549 LVNC cells
(Figure 7b).

Figure 7. Cells Transduced with LV3 Showed Attenuated Migration Towards EGF
(A) MDA-MB-231 Luc LV3 and LVNC cells were plated in the upper chamber of a
BioCoat transwell and stimulated with either 0.1% BSA or 50µg/ml EGF. The LV3 cells
which have stably reduced EphA2 receptor levels showed attenuated migration in
response to EGF when compared to the migration exhibited by the LNVC cells in
response to EGF. This result is statistically significant when analyzed using the Student’s
T-test (p-value = 0.001). (B) BT549 LV3 and LVNC cells were plated in the upper
chamber of a BioCoat transwell and stimulated with either 0.1% BSA or 50µg/ml EGF.
The LV3 cells which have stably reduced EphA2 receptor levels showed attenuated
migration in response to EGF when compared to the migration exhibited by the LNVC
cells in response to EGF, but this finding was not significant (p-value = 0.9).
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MDA-MB-231 Luc cells with Stably Reduced EphA2 Levels Show No Change in
Anchorage Independent Growth Capability
The ability of cells to grow and colonize in soft agar indicates that they are malignant
(99). Since EphA2 has been found to play a role in other hallmark processes of cancer
such as migration and angiogenesis, it was thought that maybe it plays a role in
anchorage independent proliferation and growth as well. 231 Luc, 231 Luc LVNC, and
231 Luc LV3 cells were suspended in soft agar containing either 1%FBS or 10%FBS. At
the end of two weeks, the colonies that had formed were counted. There was no
significant difference between the cell lines, revealing that reducing the receptor levels of
EphA2 does not affect the anchorage independent growth characteristic of these breast
cancer tumor cells (Figure 8).

Figure 8. Reduced Levels of EphA2 Do Not Affect Anchorage Independent Growth
(A) MDA-MB-231 Luc, MDA-MB-231 Luc LVNC, and MDA-MB-231 Luc LV3 cells
were plated in either 10% FBS or 1% FBS agarose solution and allowed to grow for 14
days. All cell lines showed a reduced number of cell colonies formed per field when
plated in 1% FBS agarose solution and showed an increase in the number of cell colonies
formed per field when plated in the agarose solution containing 10% FBS. The reduction
in EphA2 receptor levels did not affect the ability of breast cancer cells to colonize
independent of adherence and in reduced FBS conditions.
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Results: In vivo Studies

Mammary Fat Pad Tumor Growth was Reduced in Mice Injected with the Stable
MDA-MB-231 Luc LV3 Cell Line
Female athymic nude mice were injected in the mammary fat pad with either MDA-MB231 Luc LVNC or MDA-MB-231 Luc LV3 cells to observe any differences in the
tumorigenic ability between the two cell lines. Ten mice were injected with the LVNC
cell line and ten mice were injected with the LV3 cell line. Tumor measurements were
recorded and tumor volumes were calculated. Averages of the tumor volumes for each
time point in each group were compared. Over the course of five and a half weeks, the
mammary fat pad tumors of mice injected with MDA-MB-231 Luc LV3 cells showed a
decrease in growth compared to the control group (Figure 9a). This indicates that EphA2
plays a role in tumorigenicity in vivo. Furthermore, analysis of the tumor weights of the
LVNC and LV3 MFP tumors revealed a decrease in the average weight of the LV3 MFP
tumors when compared with the LVNC average tumor weight (Figure 9b).

Figure 9. Mammary Fat Pad Tumors with Stably Reduced EphA2 Showed
Decreased Tumor Growth
MDA-MB-231 Luc LVNC and MDA-MB-231 Luc LV3 cells were injected into the
mammary fat pads of female athymic nude mice. After the tumors were established, the
tumor dimensions were recorded and volumes were calculated. (A) Over the course of
5.5 weeks, the mammary fat pad tumors of the mice injected with the LV3 cells showed
reduced tumor growth compared to the mammary fat pad tumors of those mice injected
with the LVNC cells. This difference was significant as determined by the Student’s Ttest (p-value = 0.04) and was reproduced after a repeat experiment was conducted. (B) At
the time of mice sacrifice, the MFP tumors were collected and weighed. Average tumor
weight of the LVNC group is higher compared to the LV3 group. This data was not
statistically significant (p-value = 0.347).
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Tumor Protein Analysis Revealed Decreased EphA2 Protein Levels in the
Mammary Fat Pad Tumors of Mice Injected with MDA-MB-231 Luc LV3 Cells
Having seen a reduction in mammary fat pad tumor growth in those mice that were
injected with the MDA-MB-231 Luc LV3 cell line, the next step was to analyze the
protein content of the tumor tissue to assess whether the decrease in tumor growth
correlated with a reduction in tumor EphA2 protein levels. Western blot analysis revealed
that EphA2 is reduced in the MDA-MB-231 Luc LV3 mammary fat pad tumors
compared to the MDA-MB-231 Luc LVNC mammary fat pad tumors (Figure 10a).
Further densitometry analysis confirmed a reduction in EphA2 levels in the MDA-MB231 Luc LV3 mammary fat pad tumors relative to the average EphA2 content found in
the control tumors (Figure 10b). Since a reduction in EphA2 led to a reduction in EGFR
in the transient knockdown in vitro studies, the stable mammary fat pad tumor tissue
protein lysates were also analyzed for EGFR protein levels (Figure 10a,c). It appears that
there is a trend in EphA2 and EGFR protein levels in the stable mammary fat pad tumors
where a reduction in EGFR correlated with the decrease in EphA2 protein levels. This
trend was confirmed by densitometry analysis. While these data indicates a correlation in
EphA2 protein levels and tumor growth, it was not found to be statistically significant.

Figure 10. EphA2 Protein Levels Were Decreased in Mammary Fat Pad Tumors
with Stably Reduced EphA2
(A) Protein was isolated from MDA-MB-231 Luc LVNC and MDA-MB-231 Luc LV3
mammary fat pad tumor tissue and subjected to western blot analysis to reveal EphA2,
EGFR, and actin protein levels. Actin was blotted for to ensure that equal amounts of
protein were loaded. 20µg of protein was loaded into each lane. Lanes 1-5 represent five
distinct MDA-MB-231 Luc LVNC mammary fat pad tumors and lanes 6-10 represent
five distinct MDA-MB-231 Luc LV3 mammary fat pad tumors. (B) Densitometry
analysis confirmed the data obtained from the western blot analyses. The individual
EphA2 protein densities of the MDA-MB-231 Luc LVNC mammary fat pad tumors were
compared to their respective actin densities (EphA2/actin) and then all of the individual
LVNC protein densities were averaged and the average was divided by itself to obtain a
reference point of 1. The individual EphA2 protein densities of the MDA-MB-231 Luc
LV3 mammary fat pad tumors were compared to their respective actin densities
(EphA2/actin) and the divided by the average of the LVNC densities to show the amount
of EphA2 protein reduction in the individual LV3 mammary fat pad tumors relative to the
negative control mammary fat pad tumors. (C) The same method of densitometry
analysis described in (B) was applied to the EGFR protein densities to show a correlation
in EphA2 reduction and EGFR reduction.
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The MVD in MDA-MB-231 Luc LV3 Mammary Fat Pad Tumors was Reduced
Compared to the MVD in MDA-MB-231 Luc LVNC Mammary Fat Pad Tumors
Previous tumor growth and tumor protein analysis indicated that the MDA-MB-231 Luc
LV3 cells exhibited slower growth and also had reduced amounts of EphA2 protein when
compared to the control tumors. Since angiogenesis, like proliferation, is a hallmark of
cancer, it was hypothesized that reduced EphA2 would also affect vessel growth and
formation in the MDA-MB-231 Luc LV3 tumors. CD31 staining was carried out on
tissue sections prepared from MDA-MB-231 Luc LVNC and MDA-MB-231 Luc LV3
mammary fat pad tumors (Figure 11a,b). Tissue sections were observed under 20x
magnification and vessel density was quantified by counting the number of individual
vessels inside a 0.25 x 0.25mm grid. Tumor vessel density was modestly, but
significantly reduced in the MDA-MB-231 Luc LV3 tissue sections when compared to
the MDA-MB-231 Luc LVNC vessel density (Figure 11c). Staining for Ki-67 and
cleaved caspase 3 was also done, although, this data was uninformative because it did not
reveal a difference between the LVNC and LV3 tumor tissue samples (data not shown).

Figure 11. Reduced MVD in MDA-MB-231 Luc LV3 Mammary Fat Pad Tumors
Compared to MDA-MB-231 Luc LVNC
(A) CD31 stained MDA-MB-231 Luc LVNC tumor tissue sections revealed a high
microvascular density and more vessels with visible lumens. (B) CD31 stained MDAMB-231 Luc LVNC tumor tissue sections revealed a lower microvascular density with
fewer vessels having visible lumens when compared to the LVNC stained tissue sections.
(C) Vessel density was counted in ten different locations within one tumor section (each
tumor section being from a different mouse mammary fat pad tumor) and then averaged
to get a representative number of vessels per field. Quantification of the vessel density
revealed a statistically significant (p-value = 0.002) reduction in the number of vessels
per field in the CD31 stained MDA-MB-231 Luc LV3 tumor tissue sections.

Figure 11
Reduced MVD in MDA-MB-231 Luc LV3 Mammary Fat Pad Tumors Compared to
MDA-MB-231 Luc LVNC
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MDA-MB-231 Luc LV3 Cells Develop Fewer Experimental Lung Metastases in
Comparison to LVNC Cells After Intravenous Injection into Mice
Athymic female nude mice were injected i.v. with either MDA-MB-231 Luc LVNC or
MDA-MB-231 Luc LV3 cells in order to observe the efficiency of the two cell lines in
developing experimental metastases. Intravenous injections allows for cell circulation and
ultimate arrest in the capillary beds of various tissues. The development of lung
metastases was measured using the IVIS (Caliper) after i.p. injection of luciferin.
Luciferin is oxidized in the presence of luciferase (expressed by the MDA-MB-231 Luc
cells) and light energy is a by-product. This light energy, or luminescence, can be
detected and quantified by the IVIS machine. Based on initial readings at 3 and 4 weeks
after injection, more mice in the LVNC group developed lung metastases compared to the
LV3 group (Figure 12a). This suggests that breast cancer cells with reduced EphA2 are
not as efficient at developing lung metastases as the cells that over express EphA2.

Figure 12. Breast Cancer Cells with Stably Reduced EphA2 Expression Do Not
Develop Lung Metastases As Efficiently as Breast Cancer Cells Overexpressing
EphA2
MDA-MB-231 Luc LVNC or LV3 cells were injected intravenously into athymic female
nude mice. 1x106 cells suspended in 0.2ml PBS were injected in each mouse and there
were 10 mice per cell line. (A) Four weeks post-i.v. injection, the mice were imaged after
being injected i.p. with 0.2ml of luciferin (15mg/ml). Imaging of the LVNC mice
revealed lung metastases in 5 of the 9 mice (the two upper images). This number had
increased from imaging done the week before where only 2 of the 9 mice displayed lung
metastases. In contrast, imaging of the LV3 mice revealed that only one of the ten mice
had a lung metastasis and another mouse had a possible bone metastasis (the two upper
lower images). There was no additional development of lung metastases or other bodily
metastases in these two mice when compared to imaging done the previous week, and the
additional mice in the LV3 group had still not developed metastases at all.

Figure 12
Breast Cancer Cells with Stably Reduced EphA2 Expression Do Not Develop Lung
Metastases As Efficiently as Breast Cancer Cells Overexpressing EphA2

(A) IVIS Imaging LVNC and LV3 Mice: 4 weeks After Injection
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Discussion: Utilize Targeted shRNA to Study the Effects of Stable
EphA2 Reduction In vitro and In vivo

The goal of Specific Aim I was to develop a stable knockdown of EphA2 in
metastatic breast cancer cell lines to study the effect of receptor depletion over an
extended period of time. Metastatic breast cancer cell lines with a stable knockdown of
EphA2 were used to complete in vitro experiments for properties indicating metastatic
potential that have helped to confirm the findings of the transient siRNA experiments, in
which EphA2 was only maximally reduced for a few days. Use of these cell lines with
stably depleted EphA2 expression also assisted in determining how EphA2 influences
tumorigenicity in vivo, a process that cannot be successfully studied using transient
siRNA-mediated knockdown. These in vitro and in vivo experiments have helped to
reinforce the hypothesis that EphA2 contributes to the ability of breast cancer cells to
metastasize.
First and foremost, it was imperative to find a way to stably reduce EphA2
receptor expression in metastatic breast cancer cell lines. The first attempt involved the
transformation of competent bacterial cells by introducing EphA2 shRNA constructcontaining plasmids to the cells and subsequently amplifying the cultures. In addition to
containing an EphA2 shRNA construct, the plasmids also carried a puromycin resistance
gene so that transfected cells could be selected for based on their resistance. Despite
successful transfection of the cells with the EphA2 shRNA-containing plasmids
(assuming puromycin resistance is indicative of successful cellular uptake of the
plasmid), there was no reduction in EphA2 receptor levels, or if there was, it was too

minimal to expect significant results if used for in vitro and in vivo experiments. After
several unsuccessful attempts to stably reduce EphA2 after plasmid transfection, a
mixture of 3-5 lentiviral vector plasmids with shRNA sequences targeting EphA2 were
purchased from Santa Cruz in hopes that this alternative method would proved the
desired stable knockdown. However, these lentiviral particles were not successful either.
Next, the EphA2 siRNA sequences that worked very well for transient knockdown were
used to create shRNA sequences. After packing these sequences in lentiviruses, they were
used to transfect cells. Again, these did not produce the desired stable EphA2 knockdown
result. Ultimately, the custom made lentivirus #3 (described in the Materials and
Methods) containing the EphA2 shRNA construct obtained using Invitrogen’s RNAi
Designer ended up being the only vector that led to a significant and stable depletion of
EphA2 at both the protein and mRNA levels in two metastatic breast cancer cell lines
(Figure 6). The point of describing the various attempts that were made to achieve a
stable knockdown of EphA2 is metastatic breast cancer cell lines is to convey the
message that the in vitro and in vivo results based on stable EphA2 receptor knockdown
would have been strengthened if they could have been repeated using an additional
shRNA construct, but this turned out to be unachievable with the numerous methods
tested to date. Therefore, the experiments were carried out with the use of only one
lentiviral vector plasmid containing an EphA2 encoding shRNA sequence, LV3.
EphA2 has been implicated to play a role in migration in the head and neck
carcinoma cell line, HN5, and in the A431 cell line (100). Not only is EphA2 expression
upregulated by EGF-activated EGFR, but treatment of the aforementioned cell lines with
EphA2-targeting siRNA resulted in an inhibition of migration as determined by wound

healing assays (100). In addition, EGF has been shown to induce migration of MDA-MB231 breast cancer cells, but this finding did not include EphA2 as a part of the
mechanism. This EGF-induced migration of metastatic breast cancer cells was confirmed
and expanded upon by the work done in this thesis in the MDA-MB-231 Luc and BT549
cells (Figure 7). The use of EphA2 siRNA in these migration experiments revealed that
EphA2 is most likely a participant in this EGF-activated EGFR migratory pathway and
other studies using alternative cancer models have shown this to be the case as well (100,
101). The hypothesis that EphA2 plays a role in the metastatic process by affecting the
migratory ability of breast cancer cells was first confirmed by using EphA2 siRNA to
reveal a reduction in EGF-induced migration. Lentiviral transduction of BT549 and
MDA-MB-231 Luc cells with either the non-targeting or EphA2-targeting constructs was
performed to show that the breast cancer cell lines with stably reduced EphA2 still
showed a reduction in EGF-induced migration, thus confirming the results obtained with
transient silencing of EphA2. The mechanism underlying this reduced migration is still
being elucidated, but it has been demonstrated that activated EGFR phosphorylates Akt
which serine phosphorylates EphA2, leading to the formation of a protein complex,
subsequent activation of Rac1, and initiation of migration (102, 103).
To continue investigating the effects of stable EphA2 receptor knockdown,
anchorage-independent growth assays were conducted to see if EphA2 might play a role
in the ability of breast cancer cells to grow independent of attachment to plastic (Figure
8). Normal epithelial cells usually cannot survive detachment from the extracellular
matrix (101, 104). Once detached, these cells undergo programmed cell death called
anoikis (104). However, metastatic cancer cells have acquired the ability to overcome cell

death as a result of ECM detachment and can survive longer in suspension (104). This
gives cancer cells the ability to survive after dissociation from the primary tumor where
they now have a high likelihood of metastasizing (101, 104). Suspension of MDA-MB231 Luc LVNC and MDA-MB-231 Luc LV3 cells in agar containing either 10% FBS or
1% FBS did not reveal any anchorage independent growth differences between the cell
lines. This result suggests that EphA2 does not play a role in anchorage independent
growth of these cells. One study suggests that EphA2 expression is restricted to adherent
cells and is actually decreased upon detachment from plastic in vitro (101). Therefore, it
is possible that stably reduced EphA2 expression does not affect the anchorage
independent growth of metastatic breast cancer cells and the downregulation after cell
detachment seen in this previous study may be an explanation as to why there is no
difference between the MDA-MB-231 Luc LVNC and MDA-MB-231 Luc LV3 cell
lines.
Another use for the stable knockdown cell lines is to elucidate the effect that
EphA2 may have on tumorigenicity in the mammary fat pad of mice. Delivery of siRNA
to mammary fat pad tumors is one strategy to study how receptor knockdown influences
tumor growth and other properties after tumor establishment, but it cannot indicate the
role that reduced EphA2 plays in the actual tumor establishment process. Athymic female
nude mice that had been injected in the mammary fat pad with MDA-MB-231 Luc LV3
showed decreased tumor growth when compared to the mice injected with the MDA-MB231 Luc LVNC cells (Figure 9). This experiment was repeated and the resultant data
confirmed the findings these initial findings. It appears that EphA2 did affect the ability
to form tumors in the mammary fat pad although it is not clear exactly what is happening

here. Protein analysis by western blot and densitometry confirmed that the LV3
mammary fat pad tumors had decreased EphA2 protein levels and had a slight reduction
in EGFR protein levels as well (Figure 10). However, given that EphA2 does not play a
well-characterized role in cell growth and proliferation in MDA-MB-231 cells (101), it is
unknown exactly how proliferation is being affected. EphA2 may not be affecting tumor
growth directly, however, given the established role of EGFR in promoting cancer cell
proliferation, it is possible that the decrease in tumorigenicity is actually an indirect effect
of EphA2 somehow reducing the EGFR levels in the tumor cells (101). However,
staining for proliferation and apoptosis markers (Ki-67 and cleaved caspase-3) did not
show any differences between MDA-MB-231 Luc LVNC tumor sections and MDA-MB231 Luc LV3 tumor sections. These results could be due to the relatively small difference
in tumor sizes between the LVNC and LV3 groups, or it could be due to inadequate
sampling of slides. Staining tumor tissue sections for CD31 revealed a significant
decrease in the density of microvessels in the LV3 tumors compared to the LVNC tumors
(Figure 11), but in vitro studies assaying for VEGF concentrations in the EphA2 reduced
cells did not reveal a difference in concentration compared to the control cells. However,
other cytokines regulating angiogenesis may be altered. For example, it is possible that
EphA2 receptor depletion may have more of an effect on matrix metalloproteinases,
MMPs, which are also involved in the angiogenic process (105). The trend seen in
decreased EphA2 and decreased microvascular density in tumor tissue remains unclear. A
more comprehensive investigation, such as expression profiling of RNA from tumor
tissues, might provide insight into why the tumors with lower EphA2 expression grew
more slowly than the control counterparts.

Furthermore, stable knockdown of EphA2 was required to understand the role this
receptor plays in the development of metastases in vivo. Intravenous injection of the
MDA-MB-231 Luc LVNC or LV3 cells into mice revealed a correlation between reduced
EphA2 and a decrease in the number of mice that developed lung metastases (Figure 12).
This suggests that EphA2 plays a role in the ability of cancer cells to establish secondary
tumors once they have dislodged from the primary tumor, entered circulation, and
arrested in the capillary beds of other tissues within the body. Reducing the expression of
EphA2 in EphA2-expressing breast carcinomas might be one way to reduce the incidence
of metastasis.
The results of the in vitro and in vivo experiments involving MDA-MB-231 Luc
and BT549 cells with stably reduced EphA2 clearly show that there is a trend between
diminished receptor levels, decreased migration, decreased tumorigenicity, decreased
vessel formation, and reduced development of lung metastases, although, the exact
cellular mechanics behind these findings are still unclear. Further work needs to be done
to strengthen the current results and to elucidate the pathways involved.

- Chapter 4 Specific Aim II: siRNA-Mediated Transient
Reduction of EphA2

Specific Aim II: Utilization of Targeted siRNA to Study the Effect of
Transient EphA2 Reduction In vitro and In vivo

Introduction
Since its discovery, EphA2 has been found to be upregulated during specific
developmental processes and also during the process of mammary branching
morphogenesis in the pubescent female breast (43, 47, 48, 51). However, aside from
these two key periods of upregulation, EphA2 expression is low and limited to epithelial
tissues (53, 54). Interestingly, this normal pattern of EphA2 expression is disrupted
during the development of aggressive carcinomas such as those of the prostate, pancreas,
and ovaries, where EphA2 is aberrantly regulated which results in receptor
overexpression (63, 65, 66). Similar to the aforementioned types of cancer, EphA2
overexpression is also consistently found in the more aggressive and metastatic breast
cancers (77). Investigation into the role of EphA2 in the process of malignant
transformation of normal breast epithelium has identified it as an oncoprotein whose
overexpression can single-handedly promote normal cell transformation to a cancerous
and subsequently metastatic state (50, 53). Furthermore, molecules whose aberrant
regulation or expression is classically associated with cancer promotion have been found
to regulate EphA2. Such molecules include the estrogen hormone, E-cadherin, and
LMW-PTP. Indeed, dysregulation of these molecules contributes to the overexpression
and cancer-promoting functions of EphA2 (53, 59, 75, 76, 84).
The overexpression of EphA2 exhibited in aggressive forms of various cancers
with high metastatic potential has made it the focus of investigations aiming to define and

target novel molecules that have potential therapeutic significance (106). Smallinterfering ribonucleic acid (siRNA) that targets EphA2 mRNA to transiently reduce
protein levels was shown to attenuate pancreatic tumor growth in xenograft models (64).
Furthermore, EphA2-targeting siRNA delivered in 1,2-Dioleoyl-sn-glycero-3phosphatidylcholine (DOPC) neutral liposomes had a similar negative affect on tumor
growth in ovarian cancer studies (95, 107). In breast cancer, adenoviral vectors
constructed to express the EphA2 ligand, ephrinA1, were introduced to breast cancer cell
lines and demonstrated reduced tumorigenic potential after EphA2 receptor depletion
(62). In addition, ectopic overexpression of EphA2 could be reversed by using an EphA2targeting antibody, which resulted in an increase in sensitivity to chemotherapeutic agents
(108). However, while various methods have been utilized in breast cancer studies to
reduce EphA2 levels, the siRNA transient silencing approach and its ability to affect
indicators of tumorigenic and metastatic potential in vitro and in vivo hasn’t been
extensively studied.
The goal of Specific Aim II is to elucidate the affect of EphA2-targeting siRNA in
vitro and in vivo with the intention of more fully understanding the biology behind this
receptor’s mechanism of action and possibly identifying a novel therapy for the treatment
of metastatic breast cancer. A variety of breast cancer cell lines were analyzed for
EphA2 protein expression levels and a few specific, overexpressing lines were chosen for
use in this study. Initial experiments revealed the efficacy of different EphA2-targeting
siRNA’s in successfully reducing receptor protein levels. The optimal siRNA constructs
were then used to treat cells prior to conducting various in vitro experiments such as
migration assays, proliferation assays, and growth factor release assays, all of which

would aid in determining the effect of EphA2 protein reduction on metastatic potential. In
vivo studies were carried out by monitoring the effect of treating established mammary
fat pad tumors with EphA2-targeting siRNA delivered in either DOPC liposomes or
attached to chitosan nanoparticles. Tumor volume and weights were recorded and posttreatment analysis of tumor tissue included an evaluation of EphA2 protein levels, tumor
cell proliferation, and microvascular density.

Results: In vitro Studies

Demonstration of EphA2 Expression at the Protein and mRNA Levels in a Variety
of Breast Cancer Cell Lines
Protein isolated from a panel of breast cancer cell lines, with varying degrees of
aggressiveness and metastatic potential, was subjected to western blot analysis to reveal
differences in the levels of EphA2 protein expression within the various lines (Figure
13a). Furthermore, RNA isolated from this same panel of breast cancer cell lines was
analyzed by qPCR to quantify levels of EphA2 mRNA (Figure 13b). The breast cancer
cell lines with the highest EphA2 protein levels had correlating mRNA levels, and
according to the breast cancer subtype classification system proposed by Neve et al, the
majority of those cell lines with robust EphA2 expression are also of the basal subtype
(8). This confirms and establishes reports that have found a correlation between ERnegative, basal subtype breast cancers and EphA2 overexpression (7, 26, 33, 75). As
previously mentioned, the majority of breast cancer-related deaths result from the disease
developing metastatic capabilities and causing complications at distant, secondary sites
(3). Based on the expression data collected and the knowledge that metastasis is a serious
clinical challenge, the MDA-MB-231, HCC1954, and BT549 cell lines were chosen to be
the chief cell lines used in my studies due to their relative aggressiveness and high
EphA2 expression (89).

Figure 13. EphA2 Protein and mRNA Expression Levels
Western blot analysis of protein lysates collected from twelve breast cancer cell lines
and probed with an anti-Eck/EphA2 monoclonal antibody. The separated protein
lysates were also probed with an anti-actin antibody to ensure equal protein loading.
High EphA2 protein levels were shown to be expressed by a majority of the basal
subtype breast cancer cell lines. This unpublished data was provided by a previous
member of the lab. (B) Total RNA was extracted from the same twelve breast cancer
cell lines and used to carry out quantitative PCR analysis. EphA2 mRNA levels were
elevated in the same cell lines that had elevated EphA2 protein levels.
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Use of EphA2-Targeting siRNA to Transiently Reduce Protein Levels in the MDAMB-231, HCC1954, and BT549 Cell Lines
Small-interfering RNA’s are double-stranded RNA’s that are normally 20-25 nucleotides
in length. The two strands are hybridized in such a way that there is a single stranded
over-hang at either 3’ end. Transfection reagents make the cell membrane permeable so
that siRNA can enter. Once inside the cell, the siRNA is incorporated into a complex
called a RNA-Induced Silencing Complex (RISC) that has endonuclease activity. The
siRNA is unwound and directs the entire complex to a complementary messenger RNA
(mRNA) to which the complex binds, cleaves, and subsequently destroys (109, 110).
Two siRNA constructs purchased from Ambion (Applied Biosystems) that target EphA2
mRNA were shown to work effectively in various cell lines to transiently reduce EphA2
protein levels. These two siRNA constructs were used to treat the MDA-MB-231 Luc
(Figure 14a), HCC1954 (Figure 14b), and BT549 (Figure 14c) cell lines to achieve
successful transient knockdown. MDA-MB-231 Luc cells treated with the targeting
siRNA’s exhibited an almost complete knockdown of EphA2 protein, with HCC1954 and
BT549 cells achieving similarly high levels of protein reduction.

Figure 14. siRNA-Mediated Transient Reduction of EphA2 Protein Levels
Lanes are designated as one of the following: U. Untreated cells HiP. Hiperfect
transfection reagent added to cells NC. Non-targeting siRNA construct added to cells in
addition to Hiperfect transfection reagent T1. Cells treated with EphA2-targeting siRNA
#1 (146) plus Hiperfect transfection reagent T2. Cells treated with EphA2-targeting
siRNA #2 (242) plus Hiperfect transfection reagent. (A) MDA-MB-231 Luc cells
revealed successful EphA2 transient knockdown after treatment with the targeting siRNA
constructs in comparison to treatment with the non-targeting siRNA construct. (B) HCC
1954 cells revealed successful EphA2 transient knockdown after treatment with the
targeting siRNA constructs in comparison to treatment with the non-targeting siRNA
construct. (C) BT549 cells revealed successful EphA2 transient knockdown after
treatment with the targeting siRNA constructs in comparison to treatment with the nontargeting siRNA construct.
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Cells with Transiently Reduced EphA2 Protein Levels Exhibited a Decrease in
Migratory Ability Towards Chemoattractants
The migratory ability of breast cancer cells is important because it allows for progression
to an invasive and metastatic state (111). In response to 50ng/ml EGF, MDA-MB-231
Luc and BT549 cells left untreated, treated with the Hiperfect transfection reagent alone,
or treated with non-targeting siRNA showed greater migration than those cells with
transiently reduced EphA2 (Figure 15a,b). HCC1954 cells showed modest differences in
migration when comparing control cells with EphA2-reduced cells. This subtleness could
be due to the amplification of HER2/neu which could work through other pathways to
stimulate migration, overcoming the effect of EphA2 depletion on migration towards
EGF in this cell line (results not shown).

Figure 15. Transient EphA2 Reduction Attenuates Migration Towards
Chemoattractants
(A) MDA-MB231 Luc cells were either left untreated, treated with the Hiperfect
transfection reagent alone, treated with non-targeting siRNA, or treated with one of two
EphA2-targeting siRNA. Cells were then collected, suspended in serum-free media, and
placed in the upper portion of a transwell chamber. The lower portion contained either
0.1% BSA in medium or 50ng/ml EGF in medium. Cells were incubated and allowed to
migrate for 6 hours after which they were fixed, stained, and migrated cells were
quantified. Cells that had been treated with the EphA2-targeting siRNA showed
attenuated migration in comparison to the various controls. Application of the Student’s
t-test found this data to be statistically significant when comparing migration of the
knockdown cell lines towards EGF and the negative control cell line towards EGF. The
p-value was 0.02 for T1 and 0.002 for T2. (B) BT549 cells were either left untreated,
treated with the Hiperfect transfection reagent alone, treated with non-targeting siRNA,
or treated with one of two EphA2-targeting siRNA. Cells were then collected, suspended
in serum-free media, and placed in the upper portion of a transwell chamber. The lower
portion contained either 0.1% BSA in medium or 50ng/ml EGF in medium. Cells were
incubated and allowed to migrate for 6 hours after which they were fixed, stained, and
migrated cells were quantified. Cells that had been treated with the EphA2-targeting
siRNA showed attenuated migration in comparison to the various controls. Application of
the Student’s t-test found this data to be statistically significant when comparing
migration of the knockdown cell lines towards EGF and the negative control cell line
towards EGF. The p-value was 0.0004 for T1 and 0.0002 for T2.
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Investigation into the Relationship between EphA2 and EGFR in Promotion of
Cancer Cell Migration
The EphA2-EGFR relationship has been explored in other cancer cell lines. EGFR
activation by its ligand was shown to induce EphA2 expression in the human head and
neck carcinoma cell line, HN5, and in a cell line derived from a human epidermoid
carcinoma in the vulva, A431 (100). Further studies have revealed that EphA2 and EGFR
colocalize on the plasma membrane of these cells and can be co-immunoprecipitated,
providing evidence that these two receptors physically interact (100). Furthermore,
EphA2 knockdown reduced cell migration towards EGF, suggesting that the EphA2
receptor plays a role in EGF-stimulated motility in these cells (100). We sought to find
out if the same relationship existed in breast cancer cell lines since EphA2 depletion also
leads to reduced EGF-stimulated migration in our cells. Western blot analysis revealed
that siRNA-mediated transient reduction of EphA2 in the MDA-MB-231 Luc and BT20
breast cancer cell lines led to reduced EGFR receptor expression (Figure 16a). Total
RNA was extracted from the same twelve breast cancer cell lines used to analyze EphA2
mRNA levels and used to carry out quantitative PCR analysis to look at EGFR mRNA
levels in these cell lines (Figure 16e). The BT20 cell line was used because it not only
expresses EphA2, but it also has EGFR amplification. The basis for using this cell line
was to ensure that there is ample EGFR for the EphA2 to interact with. Larsen et al. also
reported that the EphA2 gene is a downstream transcriptional target of the EGF-activated
EGFR pathway (100). However, when EGFR was transiently reduced in these same cell
lines EphA2 receptor levels appeared unaffected (Figure 16c,d). Possible explanations for
this will be in the discussion section.

Figure 16. Transiently Reducing EphA2 Levels Leads to a Reduction in EGFR
Expression
MDA-MB-231 Luc and BT20 cells were both treated with either EphA2 targeting siRNA
(T1 and T2) or EGFR targeting siRNA (E1, E2, and E3) to transiently reduce levels of
the corresponding protein. Membranes were then probed with EphA2 and EGFR
antibodies to reveal the quantities of the receptors in the protein lysates. (A) MDA-MB231 Luc cells treated with EphA2 siRNA (top blot) showed reduced levels of EphA2.
Subsequent probing for EGFR on the same membrane revealed a reduction in EGFR
protein levels also (middle blot). Actin was used as the control to ensure that the protein
samples were loaded equally. (B) MDA-MB-231 Luc cells were treated with EGFR
targeting siRNA that successfully reduced the EGFR protein levels (upper, right). When
probed for EphA2, no differences in EphA2 protein levels were found after treatment
with EGFR targeting siRNA (upper, left). Actin was used as the control to ensure that the
protein samples were loaded equally. (C) EGFR targeting siRNA successfully reduced
EGFR protein levels in BT20 cells. (D) EphA2 protein levels were unaffected by the
transiently reduced levels of EGFR in BT20 cells. Actin was used as the control in both
C and D to ensure equal protein loading. (E) Relative quantities of EGFR and EphA2
mRNA in a panel of breast cancer cell lines.
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EphA2 and EGFR Co-localize at the Plasma Membrane of MDA-MB-231 Luc Cells
Having seen that there is a relationship between EphA2 and EGFR protein levels when
EphA2 is transiently reduced, it was hypothesized that EphA2 and EGFR may colocalize
at the plasma membrane and could potentially interact within a complex. EphA2 and
EGFR were found to be co-localized in the HN5 and A431 cell lines, evidence that
further motivated investigation into this hypothesis (100). To visualize the location of
EphA2 and EGFR in MDA-MB-231 Luc cells, immunocytochemical fluorescent staining
was carried out (Figure 17a). Images revealed that EphA2 and EGFR do appear to
colocalize in this cell line. To confirm and enhance the validity of this finding, cells were
also stained so that they could be imaged using a confocal microscope which enables the
cells to be reconstructed in three dimensions (Figure 17b). The technique of Z-stacking
was employed which allows different planes at various depths within the cell to be
visualized (Figure 17c). This represents a way to see if the cellular EGFR an EphA2 colocalization at the plasma membrane is consistent throughout the cell, and we found that
it is. These fluorescent and confocal images revealing EphA2 and EGFR co-localization
led us to propose that the two receptors could possibly be physically interacting.

Figure 17. Demonstration of EphA2 and EGFR Co-localization
(A) MDA-MB-231 Luc and MCF7 (not shown) cells were stained for fluorescent
imaging. MCF7 served as the negative control for the specificity of reagents seeing as
they do not express EphA2 or EGFR. EphA2 and EGFR staining can be visualized on the
plasma membrane, specifically in areas of membrane ruffling, and distributed throughout
the cytoplasm. MCF7 cells have little to no endogenous expression of EphA2 and EGFR
and, when stained for these two receptors, no positive staining occurred. (B) Confocal
imaging of MDA-MB-231 Luc cells revealed co-localization of EphA2 (green, top right)
and EGFR (red, top left). Nuclear staining is shown in blue (bottom left) and the merged
image is shown in the bottom right square. (C) This image represents one of the Z-stack
images showing EphA2 and EGFR co-localization. EGFR is shown in green (top left),
EphA2 is shown in red (top right), nuclear staining is shown in blue (bottom left), and the
merged image is shown in the bottom right square. Confocal and Z-stack images were
also compared to stained MCF7 cells which did not show positive expression of EphA2
and EGFR.

Figure 17
Demonstration of EphA2 and EGFR Co-localization

(A) Fluorescent Imaging

EphA2

(B) Confocal Imaging

EGFR

Merge

(C) Confocal Imaging: Z-Stacking

Immunoprecipitation of EphA2 from MDA-MB-231 Luc Cell Protein Lysates Did
Not Pull Down of EGFR After Stimulation with EGF
Western blot analyses had previously revealed that EGFR protein levels are reduced
when cells are treated with EphA2-targeting siRNA. This led to the proposal that EGFR
and EphA2 may co-localize at the plasma membrane and interact within a complex.
Disruption of the physical interaction between EGFR and EphA2 due to transient
reduction of EphA2 levels with siRNA might destabilize EGFR at the membrane leading
to subsequent internalization and degradation of the receptor. To investigate whether or
not EphA2 and EGFR complex, co-immunoprecipitation assays were completed. Equal
amounts of protein from MDA-MB-231 Luc cells that were either stimulated with
50ng/ml EGF (+) or left un-stimulated (-) were immunoprecipitated with 5µg of mouse
anti-Eck antibody. Agarose beads were then used to precipitate any immunocomplexes.
Western blot analysis revealed that immunoprecipitation of EphA2 by an anti-EphA2
antibody does not lead to the pull down of EGFR in these breast cancer cells (Figure
18a,b).

Figure 18. Immunoprecipitation of EphA2 Does Not Lead to EGFR Pull Down
(A) MDA-MB-231 Luc cell pre-cleared protein lysates were immunoprecipitated with
either a negative control mouse IgG antibody or anti-EphA2 antibody. Subsequent
western blot analysis revealed that EGFR had not been pulled down. 20µg of the original,
non-immunoprecipitated protein lysate was set aside as a control to ensure that EGFR
was present. (B) The membrane was stripped and reblotted for EphA2 to ensure that it
had been immunoprecipitated by the anti-EphA2 antibody. EphA2 was both present in
the original whole lysate and was also successfully precipitated out. Results are
representative of multiple experiments.
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Comparison of Vascular Endothelial Growth Factor Release in Cells Treated with
Non-Targeting siRNA and EphA2-Targeting siRNA
Angiogenesis is one of the key processes required for successful tumor establishment and
growth (67). Recruitment of preexisting vessels and development of new vessels within
the tumor hinges upon proper expression and function of pro-angiogenic growth factors
and their receptors (67, 112, 113). Eph receptors and their ligands have been implicated
to be involved in the development of embryonic vasculature (114). Recently, studies have
revealed that EphA2 is important in the tumor microenvironment in order for
angiogenesis to occur for progression to metastasis (113). Furthermore, endothelial cells
lacking EphA2 do not participate in vascular assembly, nor do they participate in vascular
migration (115). Although EphA2 appears to be associated with the process of vessel
formation and growth during tumorigenesis, the specific mechanism behind this
association remains vague. Release of the vascular endothelial growth factor (VEGF) was
measured in breast cancer cell lines with reduced EphA2 to establish whether the receptor
protein reduction correlated with a decrease in VEGF release. Preliminary data suggested
that transiently reducing the EphA2 levels in MDA-MB-231 cells produced a significant
decrease in VEGF release into the supernatant (Figure 19a). However, repetition of this
experiment did not reproducibly find a strong correlation between EphA2 receptor
depletion and decreased VEGF release in the MDA-MB-231 cell line, HCC1954 cell line,
nor the BT549 cell line (Figure 19b,c).

Figure 19. VEGF Release in Metastatic Breast Cancer Cell Lines with Attenuated
Levels of EphA2 Receptor Protein Levels
(A) ELISA analysis of supernatant collected from MDA-MB-231 cells after treatment
with EphA2-targeting siRNA revealed lower levels of released VEGF compared to cells
treated with the non-targeting siRNA or with the transfection reagent alone (preliminary
result). This data was found to be statistically significant using the GraphPad Prism 5
software. (B) ELISA analysis of supernatant collected from HCC1954 cells after
treatment with EphA2-targeting siRNA revealed mildly lower levels of released VEGF
compared to cells treated with the non-targeting siRNA or with the transfection reagent
alone. These data were not statistically significant. (C) ELISA analysis of supernatant
collected from BT549 cells after treatment with EphA2-targeting siRNA revealed no
reduction in released VEGF compared to cells treated with the non-targeting siRNA or
with the transfection reagent alone.
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Results: In vivo Studies

Having accumulated some data supporting the hypothesis that transiently depleted
EphA2 levels will negatively affect in vitro assays that indicate tumor cell metastatic
capability, we wanted to see if reducing EphA2 levels with siRNA would have any effect
on established mammary fat pad tumor growth and persistence in female athymic nude
mice.
Since its discovery, the use of the RNA interference (RNAi) pathway as a method of
silencing the expression of specific genes has continually helped to advance our
understanding of basic biology and disease states (116). Introducing siRNA into a cell
results in its uptake and incorporation into the RISC (RNA-induced silencing complex)
protein complex which recognizes complementary mRNA in the cytoplasm and destroys
them (116). While RNAi is a natural part of eukaryotic processes, artificially synthesizing
and efficiently delivering siRNA to its specific target in a live animal model has proven
to be a challenge (116).
However, there are two methods of siRNA delivery that have been reported to be
successful and that we employed to deliver non-targeting or EphA2-targeting siRNA to
the mammary fat pad tumors in our experiments. The first are DOPC liposomes. DOPC is
a natural lipid used to synthesize liposomes. siRNA can be packaged within DOPC
liposomes and injected for intratumoral delivery (95, 107). We also used chitosan
nanoparticles as a route of siRNA delivery because, among other things, they are unlikely
to elicit an immune response and they are nontoxic (117). Furthermore, nanoparticles
have been shown to be more efficient than DOPC liposomes because they have a positive

charge that allows for increased transport across the cell membrane (118). Additionally,
Han et al. showed that certain ligands can be attached to the nanoparticles in order to
specifically target markers found on the surface of tumor cells (118). In their case, they
used the RGD ligand (Arg-Gly-Asp) which targeted the αvβ3 integrin expressed on
ovarian cancer cells (118). This technique could possible be applied to specifically target
EphA2 on the surface of breast cancer cells. In addition to delivering siRNA (either
EphA2 targeting or non-targeting), we also designated some groups to be treated with
chemotherapy as well. In total we had ten groups: PBS Control, PBS + Paclitaxel, DOPC
Control siRNA, DOPC Control siRNA + Paclitaxel, DOPC EphA2 siRNA, DOPC
EphA2 siRNA + Paclitaxel, Nanoparticle Control siRNA, Nanoparticle Control siRNA +
Paclitaxel, Nanoparticle EphA2 siRNA, Nanoparticle EphA2 siRNA + Paclitaxel. Those
mice that were also receiving chemotherapy were injected i.p. once weekly with 24mg/kg
of Paclitaxel. This dose was established to be effective, yet non-toxic, in preliminary
studies carried out by previous laboratory members.
Previous research has shown that fluorescently labeled DOPC liposomes injected i.v.
into mice were detected in mammary fat pad tumors of the MDA-MB-231 breast cancer
cell line (Price et al., unpublished data). This observation and the findings with a
melanoma xenograft model supported the feasibility of systemic administration to deliver
siRNA to solid tumors (119) (Figure 20).

Figure 20. Successful Delivery of Fluorescently Labeled DOPC Liposomes to MFP
Tumors
A cross section of a MDA-MB-231 Luc established mammary fat pad tumor collected 6
hours post i.v. injection of fluorescently labeled DOPC liposomes. CD31 staining is
represented by the green color, tumor cell nuclei staining is represented by the blue color,
and the fluorescently tagged DOPC liposomes are represented by the red color.

Figure 20
Successful Delivery of Fluorescently Labeled DOPC Liposomes to MFP Tumors

(Price et al., unpublished data)

Delivery of EphA2-Targeting siRNA by DOPC Liposomes or Chitosan
Nanoparticles had No Significant Impact on Tumor Growth to the Corresponding
Control
MDA-MB-231 Luc cells were injected into the mammary fat pad of female nude mice
and allowed to grow. Once the tumors became palpable, they were measured twice a
week and the volumes were calculated. Tumor growth for each group was monitored over
time and recorded as volume vs. time (Figure 21a,b,c,d). Additionally, the dates and
numbers of mice sacrificed were noted and analyzed by means of a survival curve (data
not shown). Although there was no significant difference in tumor sizes, the mice treated
with EphA2-targeting siRNA nanoparticles without paclitaxel treatment did show a
modest decrease in tumor growth and had a longer mean survival time than the
comparative control (Figure 21c). The dose of paclitaxel used in these experiments had
previously been shown to control tumor growth and be non-toxic, but it was not effective
in this experiment. Although monitoring tumor growth and animal survival are useful
ways to analyze the effect of EphA2 reduction in MFP tumors in vivo, a more direct
readout of the effect of EphA2-targeting siRNA was measured by analyzing EphA2
protein content in the tumor tissues.

Figure 21. Tumor Growth in siRNA Treated Animals
Mammary fat pad tumors were monitored and their lengths and widths were recorded as
they grew. The tumor volumes were calculated and plotted on a graph versus time. Day 0
represents the day the cells were first injected into the mammary fat pad of the mice and
all subsequent days represent the number of days post-injection. Tumor volumes of a
particular experimental group receiving EphA2-targeting siRNA were compared to the
corresponding control group receiving the non-targeting siRNA and the PBS control
group. Tumor growth can be seen in the DOPC liposome group (A), the DOPC liposome
+ Paclitaxel group (B), the nanoparticle group (C), and the nanoparticle + Paclitaxel
group (D). According to these graphs, there is no significant difference in tumor growth
compared to the respective controls in any of the groups, however, the mice treated with
EphA2-targeting nanoparticles without Paclitaxel revealed decreased tumor growth
compared to the controls. The p-value for this group was 0.5. Arrows indicate when
treatment was initiated, which was 21 days after MFP injection.
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Analysis of Tumor Protein Lysate Revealed EphA2 Protein Levels Parallel the
Trend Seen in Tumor Growth between the Various Experimental Groups
At the time of animal sacrifice, tumor tissue was collected for protein analysis. Snap
frozen tumor tissue was lysed, purified, and sampled for EphA2 protein quantities.
Western blot analysis revealed that all tumors without paclitaxel treatment had uniformly
strong EphA2 expression, the exception being those samples collected from the group
treated with EphA2-targeting siRNA chitosan nanoparticles (Figure 22a). This group had
the lowest amounts of EphA2 expression and also had decreased tumor growth over time.
Further densitometry analysis of EphA2 protein levels confirmed a slight reduction in the
tumor tissue taken from those tumors where mice had been treated with EphA2-targeting
chitosan nanoparticles in comparison their respective control (Figure 22b). Actin levels
were blotted for as a control to ensure equal protein loading. Due to the lack of
significant differences amongst those groups that also received concomitant
chemotherapy, we only analyzed tumor EphA2 protein levels in the groups treated with
the nanoparticles and paclitaxel (Figure 22c). In these particular groups, no EphA2
protein reduction was seen, and in fact, EphA2 levels were higher in these tissue lysates
when compared to any of the DOPC liposome and nanoparticle treated groups that didn’t
receive paclitaxel. All protein lysates samples were also analyzed for levels of EGFR
protein, but no correlation or trend was found from this protein analysis.

Figure 22. EphA2 and EGFR Protein Levels in Animal Tumor Tissue Treated with
PBS, DOPC Liposomes, and Chitosan Nanoparticles
(A) Western blot analysis of protein isolated from the mammary fat pad tumors collected
from the mice treated with PBS, DOPC liposomes containing either EphA2-targeting
siRNA or non-targeting siRNA, or chitosan nanoparticles containing either EphA2targeting siRNA or non-targeting siRNA revealed no obvious attenuation in EphA2
protein levels except in the group of tumors where mice were treated with EphA2targeting nanoparticles. Immunoblotting for EGFR did not reveal a trend or correlation
with EphA2 protein levels. Immunoblotting for actin served as the control to ensure that
equal amounts of protein were loaded. (B) Densitometry of the blot confirmed that
EphA2 protein levels were lower in the tumors where the mice were treated with EphA2targeting nanoparticles in comparison to the corresponding control (left). The EphA2
protein levels in those mice treated with EphA2-targeting DOPC liposomes were not
attenuated and were equivalent to the levels seen in the corresponding control (right). (C)
Protein analysis of tumors that were treated with both EphA2-targeting nanoparticles and
Paclitaxel showed enhanced EphA2 expression compared to the corresponding control
(left). Actin was blotted for to ensure equal protein loading amongst samples.
Densitometry analysis confirmed this enhanced expression (right).
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Discussion: Utilization of Targeted siRNA to Study the Effect of
Transient EphA2 Reduction In vitro and In vivo

The goal of Specific Aim II was to utilize EphA2-targeting siRNA to study the
effect of reduced receptor levels on properties indicating aggressive and metastatic
behavior in metastatic breast cancer cell lines in vitro and in mammary fat pad tumors in
vivo. EphA2 overexpression was found in the basal subtype of breast cancers at both the
protein and mRNA levels. Breast cancer cell lines of the basal subtype are clinically more
aggressive and are most infamously known for exhibiting the “triple negative” phenotype
(7, 33). This correlates with data obtained from studies done in other cancer models
where EphA2 overexpression is found in the more aggressive and metastatic cancer cell
lines (64, 66, 69).
The ability of tumor cells to migrate positively correlates with metastatic potential
because migration is crucial for tumor cell invasion, a key step in the ability of tumor
cells to escape from the confines of the primary tumor and enter into circulation (89,
120). EGFR activation by its ligand, EGF, is one example of a receptor-ligand association
that is a pertinent part of the migratory capability of tumor cells (100, 120). Larsen et al.
have shown that EphA2 is a transcriptional target of the activated EGF-EGFR pathway
and that the two receptors physically interact to induce cell motility (100). Treatment of
BT549 and MDA-MB-231 Luc cells with EphA2-targeting siRNA resulted in attenuated
migration towards the EGF chemoattractant (Figure 15). It was therefore hypothesized
that EphA2 and EGFR physically interact in order to stimulate tumor cell migration in
breast cancer cells. This hypothesis seemed logical given that a reduction in EphA2

protein levels might destabilize EGFR at the plasma membrane, leading to increased
EGFR internalization and degradation (Figure 16). With less EGFR present on the cell
surface, breast cancer cells would be unable to migrate as efficiently in the presence of
EGF compared to those cells where EphA2 had not been transiently knocked down.
However, co-immunoprecipitation studies using protein lysates from either unstimulated
or EGF-stimulated MDA-MB-231 Luc cells failed to show that precipitation of EphA2
by an anti-Eck antibody would pull down EGFR (Figure 18). There are several possible
reasons why this data did not confirm what Larsen et al. had found. Firstly, the A431 cell
line used by Larsen’s group has significantly higher physiological levels of EGFR than
the MDA-MB-231 Luc cell line due to EGFR amplification. A quantification of EGFR
receptor levels found on the cell surface of both of these cell types indicates that the
EGFR levels on the A431 cells is at least 8 fold higher than the EGFR levels found on the
surface of MDA-MB-231 Luc cells (121, 122). This receptor amplification may affect the
co-immunoprecipitation of EphA2 and EGFR. It is possible that although MDA-MB-231
Luc cells do express EGFR, the endogenous levels are not high enough to exhibit the
EGFR-EphA2 complex formation by co-immunoprecipitation analysis. Furthermore, the
MDA-MB-231 Luc cells were stimulated with EGF for 15 minutes before harvesting the
cells and collecting the protein lysate. The A431 and HN5 cell lines in the work of Larsen
et al. were stimulated with EGF for 24 hours before carrying out the coimmunoprecipitation assay. It’s possible that the MDA-MB-231 Luc cells should be
stimulated with EGF for a longer period of time in order to successfully demonstrate
EGFR pull down after precipitation of EphA2. This would be something to look into for
future experiments.

While the possible interaction of EGFR and EphA2 within a complex should
certainly continue to be a focus of investigation, a couple of recent studies have indicated
that EGFR and EphA2 may both be vital players in the migratory mechanics of breast
cancer cells without necessarily physically interacting (102, 103). Miao et al. used the
glioblastoma cell line, U373, to show that EGF-stimulated EGFR results in the activation
of Akt. When EphA2 is not being stimulated by its own ligand, ephrinA1, it serves as a
substrate for this EGFR-activated Akt leading to serine phosphorylation of EphA2 (102).
Additionally, Miao et al. were able to show that inhibiting either the activation of Akt by
EGFR or the serine phosphorylation of EphA2 by activated Akt resulted in decreased cell
migration, however, the downstream mechanism leading to migration was not elucidated
(102). More recently, Hiramoto-Yamaki et al. have produced data using breast cancer
cells that suggests that in response to EGF stimulation, Ephexin4 binds EphA2 leading to
RhoG activation and recruitment of ELMO2 and Dock4 to the Ephexin4-EphA2 protein
complex (103) (Figure 16). This activated complex activates Rac1 and leads to the
promotion of cell migration (103). They have yet to unveil how EphA2 is being activated
that is leading to Ephexin4 recruitment, but they suggest it could be the same Akt
mechanism that was shown to promote cell migration through EphA2 in the glioblastoma
cells (102, 103). Linking these two mechanisms has recently been the subject of my
investigations in metastatic breast cancer cell lines as a way to explain how EphA2 is
involved in the promotion of tumor cell migration. According to this hypothesis, siRNAmediated EphA2 reduction would certainly attenuate the migratory ability of breast
cancer cells by inhibiting the formation of the Ephexin4-EphA2-Elmo2-Dock4 protein
complex that ultimately activates Rac1 (Figure 16).

Figure 23. Proposed Mechanism of EphA2’s Role in Rac1 Activation and Cell
Migration
The proposed mechanism of EphA2 involvement in cancer cell migration begins with the
stimulation of EGFR by its ligand EGF. Once activated, EphA2 becomes activated by an
unknown mechanism. Ephexin4 is recruited to EphA2 the activated complex stimulates
the RhoG exchange of GDP for GTP so that it is now in the activated state. Activated
RhoG recruits Elmo2 and Dock4 to the protein complex. This protein complex stimulates
the Rac1 exchange of GDP for GTP, thus activating it. The entire activated complex
localizes at points of membrane ruffling to promote cell migration.

Figure 23
Proposed Mechanism of EphA2’s Role in Rac1 Activation and Cell Migration
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Whether EGFR and EphA2 are interacting within a complex to promote cell
migration, or whether Akt is acting as the intermediate between the two receptors, there
were still other dynamics of the EphA2-EGFR relationship to be explored. EphA2 has
been shown to be a transcriptional target of EGF-activated EGFR (100). To see if the
same relationship existed in breast cancer cell lines and to see if the opposite might be
true (EGFR is a transcriptional target of EphA2), MDA-MB-231 Luc and BT 20 cells
were treated with either EGFR or EphA2-targeting siRNA. In both cell lines, transient
reduction of EphA2 led to a decrease in EGFR, but transient reduction of EGFR did not
lead to a reduction in EphA2 (Figure 16). It’s possible that, even though we cannot detect
a direct assocation by the co-immunoprecipitation assay, the reduction in EphA2 leads to
increased EGFR internalization and degradation. It’s also possible that the activated
EphA2 pathway in cancer cells drives EGFR at the transcriptional level, and a reduction
of EphA2 attenuates that upregulation. However, this cannot be conclusively determined
using only siRNA methods; rather, investigating whether EphA2 signaling has an impact
on EGFR promoter activity would be more indicative whether EphA2 can regulate EGFR
expression.
At first it was puzzling to see that EGFR reduction did not lead to decreased
EphA2 levels, as suggested by work from other groups, but it was then realized that
MDA-MB-231 Luc and BT20 cells are unique. First, MDA-MB-231 Luc cells have a
constitutively activated Ras that activates EphA2 transcription (77). If the EGFR pathway
does lead to EphA2 upregulation, siRNA-mediated reduction of EGFR wouldn’t
necessarily affect EphA2 in this cell line because the constitutively activated Ras would
maintain the overexpression of EphA2 independent of EGFR (77). Additionally, BT20

cells have amplified EGFR. Even with the EGFR-targeting siRNA, the levels of
endogenous EGFR may be so high that it is not being reduced enough and transcriptional
upregulation of EphA2 is still occurring (123). In order to clarify what the true
relationship is between EGFR and EphA2 in breast cancer cells after transient reduction
of either receptor, it would be prudent to try other metastatic breast cancer cell lines that
do not possess these unique alterations. Moreover, it is also important to note that
inhibition of migration after transient reduction of EphA2 using siRNA was not only seen
with EGF used as a chemoattractant. Cells with transiently reduced EphA2 also showed
reduced migration towards CXCL12, indicating that while there may be a relationship
between EGFR and EphA2 that is modulating cancer cell migration, EphA2 also works
through other pathways to affect migration (Price et al., unpublished).
Lin et al. has indicated that EphA2 plays a large role in the angiogenic process in
ovarian cancer and it was thus hypothesized that EphA2 may play a similar role in
metastatic breast cancers (66). Measuring the concentration of VEGF release in the
supernatant of cultured cells is one indication of cellular participation in angiogenesis
because this growth factor has been found to be necessary for the recruitment and
persistence of intra-tumoral vessels (124). However, although preliminary studies
revealed that decreased EphA2 expression in MDA-MB-231 cells causes a significant
diminution in the amount of VEGF released, this result could not be repeated to achieve
the same level of significant reduction in VEGF release in either the MDA-MB-231 cells
or two other metastatic breast cancer cell lines (Figure 19). While this data is
discouraging, it’s possible that quantifying cellular release of VEGF is not the most
informative way to elucidate the effect of reduced EphA2 expression in the angiogenic

process in breast cancer cells. Lin et al. focused on examining matrix metalloproteinase
(MMP) expression in EphA2 overexpressing ovarian carcinomas where they found a
trend between high EphA2 expression and high MMP expression (124). The expression
of MMPs in metastatic breast cancer cells in the presence or absence of EphA2 was not
examined in my study and may be worthwhile to investigate in the future due to their
established role in the process of angiogenesis (105).
The conclusion that can be made from the in vivo studies whereby EphA2targeting siRNA was delivered either in DOPC liposomes or chitosan nanoparticles with
or without paclitaxel is that EphA2 siRNA nanoparticle delivery seemed to be superior to
delivery by DOPC liposomes, but only when delivered alone and not in conjunction with
chemotherapy (Figures 21). The superiority of nanoparticles to DOPC liposomes in
successfully delivering siRNA to our mammary fat pad tumors confirms what others have
found in other cancer models (96, 118). The experiment conclusions were made primarily
based on the analysis of the tumor tissue protein (Figure 22). EphA2 protein was most
reduced in the mammary fat pad tumors that had been treated with EphA2-targeting
siRNA in chitosan nanoparticles and this is also the group that showed a trend towards
decreased tumor growth. EphA2 did not seem to be reduced in the tumors of the other
treatment groups and this correlated with a lack of difference in tumor growth between
treatment groups and control groups. The lack of reduction in EphA2 protein levels seen
in the majority of the treatment groups could be attributed to a couple of different
explanations. Firstly, it’s not known if the DOPC liposomes containing the EphA2targeting siRNA succeeded in reaching the mammary fat pad tumors. It was assumed that
they did based on preliminary data revealing fluorescently labeled siRNA in DOPC

liposomes distributed throughout sections of the tumor tissue (Figure 20). This cannot be
confirmed for this particular experiment since the siRNA was not tagged this time.
Assuming the EphA2-targeting siRNA did reach the tumors, this suggests that more
siRNA needs to be delivered more frequently in order to have a significant impact on
negative impact on intratumoral EphA2 protein levels and mammary fat pad tumor
growth. Furthermore, it is not known whether the delivered siRNA had off-target effects.
Overall, the reduction of EphA2 after utilization of targeting siRNA reveals a
negative association between attenuated EphA2 protein levels and indicators of
aggressive and metastatic tumor cell behavior. Although this trend is quite clear, there is
much investigation that still needs to done to elucidate the specific mechanisms which are
associated with EphA2 reduction and decreased metastatic potential.

- Chapter 5 Summary & Conclusions

Summary

The development of any given type of cancer requires genetic and/or epigenetic
alterations that change the normal function of cells, giving them the ability to evade
homeostatic mechanisms that normally regulate cell activities (125). This may lead to
atypical cellular proliferation and subsequent development of benign or malignant tumor
formation (85). Tumor formation occurs in nearly every location within the human body
and proof of this is seen in the high number of newly diagnosed cancer cases each year,
both nationally and internationally (1). This has led to a worldwide investigation into the
process of cancer development, establishment, and metastasis (1, 85). Metastasis itself is
a complex process often involving genetic changes in addition to the original cancerinitiating mutations (85). These acquired cellular alterations allow tumor cells to invade
into the surrounding tissue and migrate to the closest vessels where they enter the
circulation and may establish secondary tumors elsewhere (metastases) (85). The
importance of tumor cells having the capability to metastasize is that these metastases are
the primary cause of cancer-related deaths in solid tumors due to the fact that they often
establish themselves in critical locations such as the lungs, brain, and bones (85).
EphA2 has been identified in many cancers to be a receptor tyrosine kinase that is
overexpressed in the more aggressive forms of the diseases (53, 61). This is true for
melanomas, ovarian cancer, lung cancer, and prostate cancer (63, 65, 126). It has been
found to increase the metastatic ability by participating in angiogenesis, migration,
invasion, and growth in these tumor models (63, 65, 66, 126). Importantly, EphA2 is
shown to be expressed not only in breast cancer cell lines, but also in clinical tumor

samples (53). The implication is that studying the biology of EphA2 participation in the
metastatic breast cancer model may prove to be important clinically as well. Furthermore,
EphA2 is consistently found to be expressed in the aggressive, triple-negative breast
cancers which are the most aggressive, the most likely to metastasize, and which have
limited treatment options due to their lack of molecular targets such as ER and HER2 (7,
33, 77). Despite the inefficient process of metastasis and the number of hindrances tumor
cells must overcome in order to successfully metastasize, metastasis is responsible for
over 90% of human cancer deaths (127). Since breast cancer deaths are included in this
percentage and because EphA2 is highly overexpressed in metastatic breast cancers, it is
a prospective target for investigation (127). While studies have been done to establish
which breast tumors and cell lines express EphA2, little has been done to indicate the role
that EphA2 plays in these aggressive and metastatic breast cancers. Therefore, it was
hypothesized that reduced EphA2 receptor levels in metastatic breast cancer cell lines and
in established mammary fat pad tumors would negatively affect the metastatic tumor cell
characteristics in vitro and would decrease tumorigenicity and tumor persistence in vivo,
respectively.
Cancer cells are intriguing in that they must acquire several characteristics in
order to successfully establish a tumor (67). They must both be self-sufficient in their
production of growth signals, while being insensitive to anti-growth signals (67). They
must also be able to evade intracellular cell death signals in order to proliferate without
limits (67). Finally, cancer cells must have a self-sustained angiogenic capability and
should be characterized by their ability to invade in order to metastasize (67). One way to
study how EphA2 participates in these processes is to investigate what happens to

metastatic breast cancer cells when EphA2 expression has been diminished. EphA2targeting siRNA and EphA2 shRNA sequences were used to achieve a transient and
stable knockdown of EphA2 in the MDA-MB-231 Luc cell line, the BT549 cell line, and
occasionally in the HCC1954 cell line (Figures 6 & 13). These three cell lines represent
metastatic breast cancer cell lines that overexpress EphA2 at both the protein and mRNA
levels.
Migration assays carried out in the presence or absence of chemoattractants when
EphA2 expression was either maintained or depleted by siRNA or shRNA revealed that
metastatic breast cancer cell migration was attenuated in the presence of the
chemoattractants in cells where EphA2 receptor levels had been reduced (Figures 7 &
15). The ability of breast cancer cells to migrate is crucial to their ability to metastasize
because they must be able to move to nearby vessels in order to intravasate and enter the
circulation (67). These findings indicate that EphA2 is a participant in the acquired ability
of metastatic breast cancer cells to migrate. Further investigation into the mechanism
behind this participation has revealed that EGFR and EphA2 co-localize and seem to
have a non-physical relationship in the promotion of tumor cell migration. Additionally,
recent data from another group has indicated that the migration mechanism in breast
cancer cells and other cancer cell types begins with EGFR stimulation by ligand, which
subsequently results in the serine phosphorylation of EphA2 by Akt (102). This has yet to
be confirmed by my studies. However, another recent study shows that EphA2 serine
phosphorylation results in the downstream activation of Rac1 which promotes cell
migration (103). Recent results that I have obtained reveal decreased Rac1 activation in
the EphA2 silenced cell lines in the presence of EGF compared to the control cells, which

showed increased Rac1 activity after EGF stimulation. Although this observation does
not directly connect the two mechanisms found by Miao et al. and Hiramoto-Yamaki et
al., it does indirectly link EGF stimulation of EGFR to increased Rac1 activation through
EphA2. In order to better confirm this hypothesized pathway, it would be helpful to look
at EphA2 serine phosphorylation in the metastatic breast cancer cell lines in the presence
or absence of an Akt inhibitor and concurrently, in the presence or absence of EGF
stimulation. Furthermore, it would be beneficial to confirm the decreased Rac1 activation
in cells with reduced EphA2 expression by also looking at the effect of EGF stimulation
in the presence or absence of Akt inhibitors on upstream participants of this proposed
pathway, such as Ephexin4, in these cells. Unfortunately, antibodies against serine
phosphorylation in EphA2 and against Ephexin4 are not commercially available and
these studies could not be completed.
The siRNA-mediated and shRNA-mediated EphA2-reduced breast cancer cell
lines were also used to elucidate the effect that EphA2 has on angiogenesis. In vitro
studies measuring VEGF concentrations in the supernatant of cells were largely
inconclusive. Preliminary studies done by members in my lab were able to show
significant reduction in the VEGF levels of cells treated with EphA2-targeting siRNA,
but I was unable to repeat this experiment to achieve the same level of significance
(Figure 19). Furthermore, qRT-PCR analysis revealed no significant change in VEGF
mRNA levels in MDA-MB-231 Luc and BT549 cells that had stably reduced levels of
EphA2 in comparison to the EphA2 expressing cells. However, CD31 staining of tumor
tissue sections of the mice with MDA-MB-231 Luc LV3 mammary fat pad tumors
revealed a significant decrease in the microvessel density compared to the control tumors

that were also stained for CD31 (Figure 11). The conclusion to be drawn from this is that
EphA2 may have an effect on the angiogenic capability of tumors, but it can not be
assessed in vitro by way of VEGF analysis. The tumor environment in vivo is much
different from the conditions in cell culture and this may be the cause of the seemingly
contradictory data. EphA2’s role in angiogenesis may not be direct and may involve
signaling through other pathways such that simply reducing EphA2 levels would not be
sufficient to see a significant decrease in VEGF. Studies done in ovarian cancer show that
EphA2 overexpression highly correlated with angiogenesis in vivo (66). This relationship
was not as clear in the metastatic breast cancer model, but that does not mean that EphA2
does not play a role in this process in breast cancer, rather, it requires further
investigation.
In vivo investigation into the ability of stably reduced EphA2 breast cancer cells
to develop metastases revealed that they are not as efficient at establishing lung
metastases as their EphA2 overexpressing counterparts (Figure 12). These data suggest
that not only is EphA2 important for breast cancer cell migration away from the primary
tumor and into circulation, but it is also important in the ability of these circulating tumor
cells to successfully establish secondary tumors elsewhere in the body. As previously
discussed, EphA2 is known for its expression in late stage, aggressive breast cancers and
these data further implicate that this overexpression is one of the mechanisms that gives
breast cancer cells increased metastatic capabilities during breast cancer progression.
Furthermore, tumor establishment using metastatic breast cancer cell lines with shRNAmediated EphA2 reduction revealed that mammary fat pad tumors with reduced EphA2
expression showed decreased tumor growth (Figure 9). This trend was first shown using

the MDA-MB-231 Luc stable cell lines and this result was repeated in a second
experiment. Athymic female nude mice were also injected in the mammary fat pad with
the BT549 stable cell lines, but tumor growth was not observed in either of the BT549
cell lines (LVNC nor LV3) suggesting that more cells may need to be injected into the
mammary fat pads for the cells to establish tumors. Subsequent Ki-67 and cleaved
caspase 3 staining of the MDA-MB-231 Luc LVNC and LV3 tumor tissue sections
collected from the above experiment did not reveal any differences in Ki-67 or cleaved
caspase 3 staining in the LVNC mammary fat pad tumor tissue sections when compared
to the LV3 mammary fat pad tumor tissue sections. The reason for decreased tumor
growth in these tumors is not related to a decrease in cellular proliferation or an increase
in cellular apoptosis, possibly due to the relatively modest growth differences in tumors.
My results suggested that the EphA2 siRNA delivery to tumors using nanoparticles in the
absence of chemotherapy was the more effective way to knockdown EphA2 receptor
expression in established mammary fat pad tumors in vivo (Figure 21). However, this
knockdown was modest when compared with the DOPC liposomes. The indication is that
while there was a modest reduction in tumor growth observed after treatment of the
mammary fat pad tumors with EphA2-targeting nanoparticles, the quantity of siRNA
delivered was not sufficient to reduce EphA2 levels to the point where tumor growth was
significantly impaired. It’s important to note that delivery of EphA2 siRNA in DOPC
liposomes has been shown to be effective in an ovarian cancer model after i.p.
administration which contrasts with our systemic administration. My results indicate that
increased doses and/or frequency of siRNA injections might lead to more conclusive
results. Another consideration is that EphA2 expression is driven through the Ras-MAPK

pathway and the MDA-MB-231 Luc cells express an activating K-Ras mutation (77). A
more effective approach to diminishing EphA2 receptor levels in this model system may
involve targeting the EphA2 gene in addition to the Ras-MAPK pathway.
In summation, the data collected from this set of experiments that sought to
elucidate the effect of EphA2 knockdown in a metastatic breast cancer model in vitro and
in vivo has revealed that EphA2 does play a role in promoting the metastatic potential of
breast cancer cells. My work has helped to establish that EphA2 seems to have the same
function in cancer progression as it does during embryogenesis and mammary branching
morphogenesis, where it aids in the migratory capability of cells. As much as I would like
to have been able to propose a model for how EphA2 is functioning in the greater scheme
of things, my work has been more important in confirming that EphA2 functions in breast
cancer cells similar to how it functions in other cancer models where the mechanisms
have already been investigated. Despite this progress, more research should be done to
better understand the effect of EphA2 receptor depletion in metastatic breast cancer cells
and tumors. It is possible that although EphA2 does assist in the cellular mechanisms that
promote metastasis, therapeutically targeting it for the treatment of metastatic breast
cancer may not confer a sufficient anti-tumoral effect as a single agent. Many molecular
targeted therapies have been shown to be more effective when combined in standard
therapies. Despite this, EphA2 is still an important receptor due to its robust expression in
nearly all metastatic breast cancer cell lines. Since triple-negative breast cancers are
largely defined by the molecular markers that they lack. Knowing that EphA2’s
expression is common in these cancers and that it is not highly expressed in other tissues
makes it a possible molecular target for cytotoxic therapy homing (128, 129). Overall,

EphA2 is an important receptor tyrosine kinase in metastatic breast cancers and the
unexplored mechanisms behind its modes of action could potentially have relevant
biologic and therapeutic significance, some of which has been elucidated by the work
done for this thesis.

Future Directions

The role of EphA2 in the metastatic capabilities of metastatic breast cancer cells
should continue to be investigated in the breast cancer model. EphA2 has been shown to
be a participant other signaling pathways, such as FAK-mediated cellular interaction with
the ECM in epithelial prostate cancer cells (60). EphA2’s role in pathways such as these
has yet to be elucidated and investigation into them may highly contribute to gaining a
more complete understanding of EphA2’s role not only in breast cancer, but in other
cancer models as well. Furthermore, as discussed in the summary, it may be that EphA2’s
unique expression on cancerous epithelial cells is going to be more clinically beneficial
than attempting to hinder the downstream signaling actions that result from EphA2
overexpression. For example, using the expression of EphA2 as a tumor homing
mechanism for cytotoxic therapy against metastatic breast cancer might be worth
exploring in future studies.
On a larger scale, the Eph receptors in general have been the target of drug
developers (130). EphA2 has specifically been the target of drug companies like
MedImmune which had an anti-EphA2 antibody program, but unfortunately, this project
was discontinued for unspecified reasons after its acquisition by Astra-Zeneca in 2008
(130). Furthermore, Pfizer has a preclinical study of an anti-EphA2 tyrosine kinase
inhibitor that is still ongoing (130). The attention given to EphA2 by drug companies
signifies that it is an important potential therapeutic target not only for breast cancer
patients, but for other cancer patients as well. However, development of anti-EphA2
therapies still has a long ways to go and it is very possible that multiple anti-Eph

therapies will be needed in order to inhibit the tumor promoting effects of this receptor
tyrosine kinase family.

Conclusions

EphA2 is overexpressed in the triple-negative, basal subtype of breast cancers and
these breast cancers are highly aggressive and metastatic. EphA2 is a participant in the
migratory ability of breast cancer cells, giving them increased metastatic ability.
Furthermore, it appears that reduced levels of EphA2 causes a decrease in the MVD of
mammary fat pad tumors, but the mechanism behind this observation is still unclear.
Additionally, reduced levels of EphA2 were found to correlate with decreased tumor
growth in vivo both after treatment of established mammary fat tumors with nanoparticles
containing EphA2 siRNA, and also in mammary fat pad tumors that were established
using EphA2-reduced breast cancer cells. While there is still much investigation that
needs to be done, this work establishes that EphA2 is important in promoting the
characteristics that allow breast cancer cells to metastasize.
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